EP1177173A1 - Hydroxamic acid derivatives as matrix metalloprotease inhibitors - Google Patents
Hydroxamic acid derivatives as matrix metalloprotease inhibitorsInfo
- Publication number
- EP1177173A1 EP1177173A1 EP00931910A EP00931910A EP1177173A1 EP 1177173 A1 EP1177173 A1 EP 1177173A1 EP 00931910 A EP00931910 A EP 00931910A EP 00931910 A EP00931910 A EP 00931910A EP 1177173 A1 EP1177173 A1 EP 1177173A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- alkyl
- aryl
- substituted
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 17
- 239000002253 acid Substances 0.000 title abstract description 80
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title abstract description 28
- 239000003475 metalloproteinase inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 328
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 228
- 238000000034 method Methods 0.000 claims abstract description 66
- 230000008569 process Effects 0.000 claims abstract description 36
- 230000000694 effects Effects 0.000 claims abstract description 33
- 102000005741 Metalloproteases Human genes 0.000 claims abstract description 28
- 108010006035 Metalloproteases Proteins 0.000 claims abstract description 28
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 19
- 230000001575 pathological effect Effects 0.000 claims abstract description 19
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 18
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 18
- -1 nitro, hydroxyl Chemical group 0.000 claims description 504
- 125000003118 aryl group Chemical group 0.000 claims description 308
- 125000001424 substituent group Chemical group 0.000 claims description 259
- 125000000217 alkyl group Chemical group 0.000 claims description 225
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 183
- 125000003342 alkenyl group Chemical group 0.000 claims description 162
- 125000001145 hydrido group Chemical group *[H] 0.000 claims description 146
- 125000001188 haloalkyl group Chemical group 0.000 claims description 121
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 119
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 118
- 150000003839 salts Chemical class 0.000 claims description 116
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 114
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 104
- 125000003545 alkoxy group Chemical group 0.000 claims description 90
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 87
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 85
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 80
- 125000003435 aroyl group Chemical group 0.000 claims description 75
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 74
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 70
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 68
- 125000000304 alkynyl group Chemical group 0.000 claims description 59
- 125000005843 halogen group Chemical group 0.000 claims description 55
- 229920001774 Perfluoroether Polymers 0.000 claims description 53
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 52
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 49
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 42
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 42
- 229910052736 halogen Inorganic materials 0.000 claims description 42
- 125000004104 aryloxy group Chemical group 0.000 claims description 41
- 125000003277 amino group Chemical group 0.000 claims description 40
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 40
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 38
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 38
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 38
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 36
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 36
- 150000002825 nitriles Chemical class 0.000 claims description 36
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 32
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 30
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims description 30
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- 125000005110 aryl thio group Chemical group 0.000 claims description 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 26
- 125000004429 atom Chemical group 0.000 claims description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 125000006239 protecting group Chemical group 0.000 claims description 24
- 125000004414 alkyl thio group Chemical group 0.000 claims description 22
- 125000004470 heterocyclooxy group Chemical group 0.000 claims description 22
- 229920006395 saturated elastomer Polymers 0.000 claims description 22
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 21
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 19
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 14
- 125000005354 acylalkyl group Chemical group 0.000 claims description 14
- 125000001931 aliphatic group Chemical group 0.000 claims description 14
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 14
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 14
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 14
- 239000011593 sulfur Substances 0.000 claims description 13
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 12
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 12
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 12
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 12
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 12
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 11
- 150000001768 cations Chemical class 0.000 claims description 11
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 11
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 10
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 10
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 10
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 10
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 10
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 10
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 10
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 8
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 7
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims description 7
- 125000001769 aryl amino group Chemical group 0.000 claims description 7
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 7
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 7
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims description 7
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 claims description 7
- 125000004476 heterocycloamino group Chemical group 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 4
- 125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims 71
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 claims 10
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 claims 1
- 101100347612 Arabidopsis thaliana VIII-B gene Proteins 0.000 claims 1
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 82
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 62
- 150000003254 radicals Chemical class 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- 239000003153 chemical reaction reagent Substances 0.000 description 30
- 235000002639 sodium chloride Nutrition 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 229910001868 water Inorganic materials 0.000 description 27
- 239000002585 base Substances 0.000 description 26
- 150000002148 esters Chemical class 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 125000002252 acyl group Chemical group 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 21
- 150000001412 amines Chemical class 0.000 description 20
- 150000003457 sulfones Chemical class 0.000 description 20
- 239000000543 intermediate Substances 0.000 description 19
- 229940124530 sulfonamide Drugs 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 17
- 229910052751 metal Inorganic materials 0.000 description 17
- 239000002184 metal Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 150000003456 sulfonamides Chemical class 0.000 description 17
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 16
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 16
- 230000003647 oxidation Effects 0.000 description 16
- 238000007254 oxidation reaction Methods 0.000 description 16
- 150000003573 thiols Chemical class 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 150000001408 amides Chemical class 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 14
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 14
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- 108050005238 Collagenase 3 Proteins 0.000 description 11
- 102100027995 Collagenase 3 Human genes 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 150000007513 acids Chemical class 0.000 description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000005804 alkylation reaction Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- WNZQDUSMALZDQF-UHFFFAOYSA-N isobenzofuranone Natural products C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 150000001450 anions Chemical class 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 210000002808 connective tissue Anatomy 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 8
- 102000003390 tumor necrosis factor Human genes 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- 102000029816 Collagenase Human genes 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 229940124761 MMP inhibitor Drugs 0.000 description 7
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000012038 nucleophile Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 102100030416 Stromelysin-1 Human genes 0.000 description 6
- 238000005903 acid hydrolysis reaction Methods 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 6
- NLXXVSKHVGDQAT-UHFFFAOYSA-N o-(oxan-2-yl)hydroxylamine Chemical compound NOC1CCCCO1 NLXXVSKHVGDQAT-UHFFFAOYSA-N 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 5
- 229950008959 marimastat Drugs 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical group OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 239000000651 prodrug Chemical group 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 150000003462 sulfoxides Chemical class 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical group OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- VUFOTXYLUWEYFC-UHFFFAOYSA-N 4-phenoxybenzenethiol Chemical compound C1=CC(S)=CC=C1OC1=CC=CC=C1 VUFOTXYLUWEYFC-UHFFFAOYSA-N 0.000 description 4
- 108091007505 ADAM17 Proteins 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 102100030417 Matrilysin Human genes 0.000 description 4
- 108090000855 Matrilysin Proteins 0.000 description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 101710108790 Stromelysin-1 Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- 229910000085 borane Inorganic materials 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 150000003949 imides Chemical class 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 150000003568 thioethers Chemical class 0.000 description 4
- 150000007944 thiolates Chemical class 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 3
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- 102000056189 Neutrophil collagenases Human genes 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Inorganic materials [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 150000001649 bromium compounds Chemical class 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 229940125532 enzyme inhibitor Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 3
- 238000006263 metalation reaction Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- FHHJDRFHHWUPDG-UHFFFAOYSA-L peroxysulfate(2-) Chemical compound [O-]OS([O-])(=O)=O FHHJDRFHHWUPDG-UHFFFAOYSA-L 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003586 protic polar solvent Substances 0.000 description 3
- 238000005932 reductive alkylation reaction Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 150000003458 sulfonic acid derivatives Chemical class 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 2
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 206010048998 Acute phase reaction Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 101100156282 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) vib-1 gene Proteins 0.000 description 2
- 108030001564 Neutrophil collagenases Proteins 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 102100028848 Stromelysin-2 Human genes 0.000 description 2
- 102100028847 Stromelysin-3 Human genes 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 2
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004658 acute-phase response Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 batimastat Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 150000001721 carbon Chemical class 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 208000002528 coronary thrombosis Diseases 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 229910000071 diazene Inorganic materials 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- LRMHFDNWKCSEQU-UHFFFAOYSA-N ethoxyethane;phenol Chemical compound CCOCC.OC1=CC=CC=C1 LRMHFDNWKCSEQU-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 150000002443 hydroxylamines Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 description 2
- 239000003774 sulfhydryl reagent Substances 0.000 description 2
- 150000003461 sulfonyl halides Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001302 tertiary amino group Chemical group 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000000464 thioxo group Chemical group S=* 0.000 description 2
- 230000008427 tissue turnover Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
- NCYNKWQXFADUOZ-UHFFFAOYSA-N 1,1-dioxo-2,1$l^{6}-benzoxathiol-3-one Chemical compound C1=CC=C2C(=O)OS(=O)(=O)C2=C1 NCYNKWQXFADUOZ-UHFFFAOYSA-N 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YQDABOFRIJYYQZ-UHFFFAOYSA-N 1,4-dimethylpiperazine;hydrate Chemical compound O.CN1CCN(C)CC1 YQDABOFRIJYYQZ-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- HLQZCRVEEQKNMS-UHFFFAOYSA-N 1-(chloromethyl)-4-phenylbenzene Chemical compound C1=CC(CCl)=CC=C1C1=CC=CC=C1 HLQZCRVEEQKNMS-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- YAYNEUUHHLGGAH-UHFFFAOYSA-N 1-chlorododecane Chemical class CCCCCCCCCCCCCl YAYNEUUHHLGGAH-UHFFFAOYSA-N 0.000 description 1
- PPNCOQHHSGMKGI-UHFFFAOYSA-N 1-cyclononyldiazonane Chemical compound C1CCCCCCCC1N1NCCCCCCC1 PPNCOQHHSGMKGI-UHFFFAOYSA-N 0.000 description 1
- ULFLWQFGULEGEV-UHFFFAOYSA-N 1-ethylpiperidin-1-ium;hydroxide Chemical compound [OH-].CC[NH+]1CCCCC1 ULFLWQFGULEGEV-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- BYCLIJFAFHKKFL-UHFFFAOYSA-N 1-phenyl-2-(4-phenylphenyl)benzene Chemical compound C1=CC=CC=C1C1=CC=C(C=2C(=CC=CC=2)C=2C=CC=CC=2)C=C1 BYCLIJFAFHKKFL-UHFFFAOYSA-N 0.000 description 1
- TXJUTRJFNRYTHH-UHFFFAOYSA-N 1h-3,1-benzoxazine-2,4-dione Chemical compound C1=CC=C2C(=O)OC(=O)NC2=C1 TXJUTRJFNRYTHH-UHFFFAOYSA-N 0.000 description 1
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 1
- KAQBNBSMMVTKRN-UHFFFAOYSA-N 2,4,6-trinitrobenzoic acid Chemical compound OC(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O KAQBNBSMMVTKRN-UHFFFAOYSA-N 0.000 description 1
- BRETYAHLENMEAI-UHFFFAOYSA-N 2,6-dimethylbenzenesulfonic acid Chemical compound CC1=CC=CC(C)=C1S(O)(=O)=O BRETYAHLENMEAI-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- JKIFPWHZEZQCQA-UHFFFAOYSA-N 2-nitrobenzenethiol Chemical compound [O-][N+](=O)C1=CC=CC=C1S JKIFPWHZEZQCQA-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZMPRRFPMMJQXPP-UHFFFAOYSA-N 2-sulfobenzoic acid Chemical class OC(=O)C1=CC=CC=C1S(O)(=O)=O ZMPRRFPMMJQXPP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VYWYYJYRVSBHJQ-UHFFFAOYSA-N 3,5-dinitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 VYWYYJYRVSBHJQ-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- MJUOQIISQATEEV-UHFFFAOYSA-M 4,4-dimethylmorpholin-4-ium;hydroxide Chemical compound [OH-].C[N+]1(C)CCOCC1 MJUOQIISQATEEV-UHFFFAOYSA-M 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NIFAOMSJMGEFTQ-UHFFFAOYSA-N 4-methoxybenzenethiol Chemical compound COC1=CC=C(S)C=C1 NIFAOMSJMGEFTQ-UHFFFAOYSA-N 0.000 description 1
- IVNPXOUPZCTJAK-UHFFFAOYSA-N 4-methylmorpholin-4-ium;hydroxide Chemical compound O.CN1CCOCC1 IVNPXOUPZCTJAK-UHFFFAOYSA-N 0.000 description 1
- QIZPONOMFWAPRR-UHFFFAOYSA-N 4-phenoxybenzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1OC1=CC=CC=C1 QIZPONOMFWAPRR-UHFFFAOYSA-N 0.000 description 1
- RVDLHGSZWAELAU-UHFFFAOYSA-N 5-tert-butylthiophene-2-carbonyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)S1 RVDLHGSZWAELAU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 229910021630 Antimony pentafluoride Inorganic materials 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- KLYCPFXDDDMZNQ-UHFFFAOYSA-N Benzyne Chemical compound C1=CC#CC=C1 KLYCPFXDDDMZNQ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OVOBNGQCLXTWFO-UHFFFAOYSA-N C[NH2+]C.C[NH2+]C.C[NH2+]C.C[NH2+]C.C(P(=O)([O-])[O-])P(=O)([O-])[O-] Chemical compound C[NH2+]C.C[NH2+]C.C[NH2+]C.C[NH2+]C.C(P(=O)([O-])[O-])P(=O)([O-])[O-] OVOBNGQCLXTWFO-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 108700034813 EC 3.4.24.17 Proteins 0.000 description 1
- 108700033382 EC 3.4.24.22 Proteins 0.000 description 1
- 108700033384 EC 3.4.24.24 Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108030001712 Macrophage elastases Proteins 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 108010013295 Microbial collagenase Proteins 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- FVRDLZIVXNCVHA-UHFFFAOYSA-N N-hydroxy-6-sulfonylcyclohexa-2,4-diene-1-carboxamide Chemical compound S(=O)(=O)=C1C(C(=O)NO)C=CC=C1 FVRDLZIVXNCVHA-UHFFFAOYSA-N 0.000 description 1
- RRKUYMMDXAYOAC-UHFFFAOYSA-N NO.N=C=O Chemical class NO.N=C=O RRKUYMMDXAYOAC-UHFFFAOYSA-N 0.000 description 1
- ZAHXYMFVNNUHCP-UHFFFAOYSA-N Naphazoline nitrate Chemical group O[N+]([O-])=O.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 ZAHXYMFVNNUHCP-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 101710151579 Zinc metalloproteinase Proteins 0.000 description 1
- IAUTZPNJHGUKIQ-UHFFFAOYSA-N [NH4+].CN1N(CCCCCCC1)C1CCCCCCCC1.[OH-] Chemical compound [NH4+].CN1N(CCCCCCC1)C1CCCCCCCC1.[OH-] IAUTZPNJHGUKIQ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- VBVBHWZYQGJZLR-UHFFFAOYSA-I antimony pentafluoride Chemical compound F[Sb](F)(F)(F)F VBVBHWZYQGJZLR-UHFFFAOYSA-I 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical group [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- JHLCADGWXYCDQA-UHFFFAOYSA-N calcium;ethanolate Chemical compound [Ca+2].CC[O-].CC[O-] JHLCADGWXYCDQA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- JHRWWRDRBPCWTF-OLQVQODUSA-N captafol Chemical compound C1C=CC[C@H]2C(=O)N(SC(Cl)(Cl)C(Cl)Cl)C(=O)[C@H]21 JHRWWRDRBPCWTF-OLQVQODUSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- JOHCVVJGGSABQY-UHFFFAOYSA-N carbon tetraiodide Chemical compound IC(I)(I)I JOHCVVJGGSABQY-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-N difluoroacetic acid Chemical compound OC(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- YYVLJSYHJIQREA-UHFFFAOYSA-N ethyl 2-chlorosulfonylbenzoate Chemical compound CCOC(=O)C1=CC=CC=C1S(Cl)(=O)=O YYVLJSYHJIQREA-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004407 fluoroaryl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 238000007871 hydride transfer reaction Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical class [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QKASDIPENBEWBU-UHFFFAOYSA-N methyl 2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1CBr QKASDIPENBEWBU-UHFFFAOYSA-N 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- FWCHISPFSGCORQ-UHFFFAOYSA-N morpholine;hydrate Chemical compound O.C1COCCN1 FWCHISPFSGCORQ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MXHTZQSKTCCMFG-UHFFFAOYSA-N n,n-dibenzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CN(CC=1C=CC=CC=1)CC1=CC=CC=C1 MXHTZQSKTCCMFG-UHFFFAOYSA-N 0.000 description 1
- JEUXZUSUYIHGNL-UHFFFAOYSA-N n,n-diethylethanamine;hydrate Chemical compound O.CCN(CC)CC JEUXZUSUYIHGNL-UHFFFAOYSA-N 0.000 description 1
- ZFRKLDBGVWUUEE-UHFFFAOYSA-N n,n-dimethyl-1-phenylmethanamine;hydrate Chemical compound [OH-].C[NH+](C)CC1=CC=CC=C1 ZFRKLDBGVWUUEE-UHFFFAOYSA-N 0.000 description 1
- PHWISQNXPLXQRU-UHFFFAOYSA-N n,n-dimethylcarbamothioyl chloride Chemical compound CN(C)C(Cl)=S PHWISQNXPLXQRU-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- UTTMHMHHOULJMD-UHFFFAOYSA-N n-(oxan-2-yl)hydroxylamine Chemical compound ONC1CCCCO1 UTTMHMHHOULJMD-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- LVCDXCQFSONNDO-UHFFFAOYSA-N n-benzylhydroxylamine Chemical compound ONCC1=CC=CC=C1 LVCDXCQFSONNDO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ISRXMEYARGEVIU-UHFFFAOYSA-N n-methyl-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C)C(C)C ISRXMEYARGEVIU-UHFFFAOYSA-N 0.000 description 1
- NCCHARWOCKOHIH-UHFFFAOYSA-N n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1 NCCHARWOCKOHIH-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YKADXBWVXZZCBU-UHFFFAOYSA-N n-trimethylsilylhydroxylamine Chemical compound C[Si](C)(C)NO.C[Si](C)(C)NO YKADXBWVXZZCBU-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- AEKHNNJSMVVESS-UHFFFAOYSA-N o-trimethylsilylhydroxylamine Chemical compound C[Si](C)(C)ON AEKHNNJSMVVESS-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000369 oxido group Chemical group [*]=O 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920002616 peptidyl amide Polymers 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 125000005003 perfluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000003279 phenylacetic acid Chemical group 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical class C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 125000005506 phthalide group Chemical group 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- ZMJJCODMIXQWCQ-UHFFFAOYSA-N potassium;di(propan-2-yl)azanide Chemical compound [K+].CC(C)[N-]C(C)C ZMJJCODMIXQWCQ-UHFFFAOYSA-N 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- UJJDEOLXODWCGK-UHFFFAOYSA-N tert-butyl carbonochloridate Chemical compound CC(C)(C)OC(Cl)=O UJJDEOLXODWCGK-UHFFFAOYSA-N 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
- 229940073455 tetraethylammonium hydroxide Drugs 0.000 description 1
- LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- GSTFRTMWAWKAGF-UHFFFAOYSA-M tribenzyl(methyl)azanium;hydroxide Chemical compound [OH-].C=1C=CC=CC=1C[N+](CC=1C=CC=CC=1)(C)CC1=CC=CC=C1 GSTFRTMWAWKAGF-UHFFFAOYSA-M 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- BJAARRARQJZURR-UHFFFAOYSA-N trimethylazanium;hydroxide Chemical compound O.CN(C)C BJAARRARQJZURR-UHFFFAOYSA-N 0.000 description 1
- JQZIKLPHXXBMCA-UHFFFAOYSA-N triphenylmethanethiol Chemical class C=1C=CC=CC=1C(C=1C=CC=CC=1)(S)C1=CC=CC=C1 JQZIKLPHXXBMCA-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention is directed to proteinase (protease) inhibitors, and more particularly to sulfonyl aryl or heteroaryl hydroxamic acid compounds that, inter alia, inhibit the activity of matrix metalloproteinases, compositions of those inhibitors, intermediates for the syntheses of those compounds, processes for the preparation of the compounds and processes for treating pathological conditions associated with pathological matrix metalloproteinase activity.
- protease proteas
- sulfonyl aryl or heteroaryl hydroxamic acid compounds that, inter alia, inhibit the activity of matrix metalloproteinases, compositions of those inhibitors, intermediates for the syntheses of those compounds, processes for the preparation of the compounds and processes for treating pathological conditions associated with pathological matrix metalloproteinase activity.
- Connective tissue, extracellular matrix constituents and basement membranes are required components of all mammals. These components are the biological materials that provide rigidity, differentiation, attachments and, in some cases, elasticity to biological systems including human beings and other mammals.
- Connective tissues components include, for example, collagen, elastin, proteoglycans, fibronectin and laminin. These biochemicals make up, or are components of structures, such as skin, bone, teeth, tendon, cartilage, basement membrane, blood vessels, cornea and vitreous humor.
- Degradation of connective tissue or connective tissue components is carried out by the action of proteinase enzymes released from resident tissue cells and/or invading inflammatory or tumor cells.
- a major class of enzymes involved in this function are the zinc metalloproteinases (metalloproteases, or MMPs) .
- the metalloprotease enzymes are divided into classes with some members having several different names in common use. Examples are: collagenase I (MMP-1, fibroblast collagenase; EC 3.4.24.3); collagenase II (MMP- 8, neutrophil collagenase; EC 3.4.24.34), collagenase III (MMP- 13), stromelysin 1 (MMP-3; EC 3.4.24.17), stromelysin 2 (MMP- 10; EC 3.4.24.22), proteoglycanase, matrilysin (MMP-7) , gelatinase A (MMP-2, 72kDa gelatinase, basement membrane collagenase; EC 3.4.24.24), gelatinase B (MMP- 9, 92kDa gelatinase; EC 3.4.24.35), stromelysin 3 (MMP-11) , metalloelastase (MMP-12, HME, human macrophage elastase) and
- the uncontrolled breakdown of connective tissue by metalloproteases is a feature of many pathological conditions. Examples include rheumatoid arthritis, osteoarthritis, septic arthritis; corneal , epidermal or gastric ulceration; tumor metastasis, invasion or angiogenesis ; periodontal disease; proteinuria; Alzheimer's Disease; coronary thrombosis and bone disease. Defective injury repair processes can also occur. This can produce improper wound healing leading to weak repairs, adhesions and scarring. These latter defects can lead to disfigurement and/or permanent disabilities as with post -surgical adhesions.
- TNF- ⁇ tumor necrosis factor
- Matrix metalloproteases are also involved in the biosynthesis of tumor necrosis factor (TNF) and inhibition of the production or action of TNF and related compounds is an important clinical disease treatment mechanism.
- TNF- ⁇ for example, is a cytokine that at present is thought to be produced initially as a 28 kD cell-associated molecule. It is released as an active, 17 kD form that can mediate a large number of deleterious effects in vi tro and in vivo .
- TNF can cause and/or contribute to the effects of inflammation, rheumatoid arthritis, autoimmune disease, multiple sclerosis, graft rejection, fibrotic disease, cancer, infectious diseases, malaria, mycobacterial infection, meningitis, fever, psoriasis, cardiovascular/pulmonary effects such as post-ischemic reperfusion injury, congestive heart failure, hemorrhage, coagulation, hyperoxic alveolar injury, radiation damage and acute phase responses like those seen with infections and sepsis and during shock such as septic shock ahd hemodynamic shock.
- Chronic release of active TNF can cause cachexia and anorexia.
- TNF can be lethal.
- TNF- ⁇ convertase is a metalloproteinase involved in the formation of active TNF- ⁇ .
- TNF- ⁇ convertase inhibits production of active TNF- ⁇ .
- Compounds that inhibit both MMPs activity have been disclosed in IPO International Publication Nos. WO 94/24140, WO 94/02466 and WO 97/20824.
- MMP and TNF- ⁇ convertase inhibiting agents Compounds that inhibit MMPs such as collagenase, stromelysin and gelatinase have been shown to inhibit the release of TNF (Gearing et al . Nature 376. 555-557 (1994), McGeehan et al . , Nature 376, 558-561 (1994) ) .
- MMPs are involved in other biochemical processes in mammals as well. Included is the control of ovulation, post-partum uterine involution, possibly implantation, cleavage of APP ( ⁇ -Amyloid Precursor Protein) to the amyloid plaque and inactivation of ⁇ - ⁇ -protease inhibitor ( ⁇ ..-PI) .
- APP ⁇ -Amyloid Precursor Protein
- ⁇ - ⁇ -protease inhibitor ⁇ ..-PI
- Inhibition of these metalloproteases permits the control of fertility and the treatment or prevention of Alzheimers Disease.
- increasing and maintaining the levels of an endogenous or administered serine protease inhibitor drug or biochemical such as ⁇ -PI supports the treatment and prevention of diseases such as emphysema, pulmonary diseases, inflammatory diseases and diseases of aging such as loss of skin or organ stretch and resiliency.
- Inhibition of selected MMPs can also be desirable in other instances.
- Treatment of cancer and/or inhibition of metastasis and/or inhibition of angiogenesis are examples of approaches to the treatment of diseases wherein the selective inhibition of stromelysin (MMP-3), gelatinase (MMP- 2) , gelatinase B (MMP-9) or collagenase III (MMP- 13) may be relatively more important than inhibition of collagenase I (MMP-1) .
- MMP-3 stromelysin
- MMP-2 gelatinase
- MMP-9 gelatinase B
- collagenase III MMP- 13
- a drug that does not inhibit collagenase I can have a superior therapeutic profile.
- Osteoarthritis another prevalent disease wherein it is believed that cartilage degradation in inflamed joints is at least partially caused by MMP- 13 released from cells such as stimulated chrondrocytes, may be best treated by administration of drugs one of whose modes of action is inhibition of MMP-13.
- Inhibitors of metalloproteases are known. Examples include natural biochemicals such as tissue inhibitor of metalloproteinase (TIMP) , ⁇ 2 ⁇ macroglobulin and their analogs or derivatives. These are high molecular weight protein molecules that form inactive complexes with metalloproteases.
- TIMP tissue inhibitor of metalloproteinase
- ACE inhibition in vi tro and in vivo .
- Angiotensin converting enzyme ACE
- ACE angiotensin converting enzyme
- Thiol group-containing amide or peptidyl amide-based metalloprotease (MMP) inhibitors are known as is shown in, for example, W095/12389,
- Hydroxamate group- containing MMP inhibitors are disclosed in a number of published patent applications such as WO 95/29892, WO 97/24117, WO 97/49679 and EP 0 780 386 that disclose carbon back-boned compounds, and WO 90/05719, WO 93/20047, WO 95/09841 and WO 96/06074 that disclose hydroxamates that have a peptidyl back-bones or peptidomimetic back-bones, as does the article by Schwartz et al . , Progr. Med. Chem . , 29:271-334(1992) and those of Rasmussen et al . ,
- MMP inhibitors One possible problem associated with known MMP inhibitors is that such compounds often exhibit the same or similar inhibitory effects against each of the MMP enzymes.
- the peptidomimetic hydroxamate known as batimastat is reported to exhibit IC50 values of about 1 to about
- Marimastat another peptidomimetic hydroxamate was reported to be another broad-spectrum MMP inhibitor with an enzyme inhibitory spectrum very similar to batimastat, except that marimastat exhibited an IC50 value against MMP-3 of 230 nM. Rasmussen et al . , Pharmacol . Ther . , 75 (1 ) : 69-75 (1997) .
- hydroxamate MMP inhibitor compounds In view of the importance of hydroxamate MMP inhibitor compounds in the treatment of several diseases and the lack of enzyme specificity exhibited by two of the more potent drugs in clinical trials, it would be a great benefit if hydroxamates of greater enzyme specificity could be found. This would be particularly the case if the hydroxamate inhibitors exhibited strong inhibitory activity against one or more of MMP-2, MMP- 9 or MMP- 13 that are associated with several pathological conditions, while at the same time exhibiting limited inhibition of MMP-1, an enzyme that is relatively ubiquitous and as yet not associated with any pathological condition.
- the disclosure that follows describes one family of hydroxamate MMP inhibitors that exhibit those desirable activities
- the present invention is directed to a family of molecules that among other properties inhibit matrix metalloprotease (MMP) activity and particularly inhibit the activity of one or more of MMP-2, MMP-9, or MMP-13, while generally exhibiting little activity against MMP-1.
- MMP matrix metalloprotease
- the present invention is also directed to intermediates useful in the synthesis of inhibitors, processes for preparing a contemplated compound and for treating a mammal having a condition associated with pathological matrix metalloprotease activity.
- one embodiment of the present invention is directed to a sulfonyl aryl or heteroaryl hydroxamic acid compound, or a pharmaceutically acceptable salt of such a compound that can act as a matrix metalloprotease enzyme inhibitor, a precursor to such a compound or a pro- drug form of such a compound.
- a contemplated compound corresponds in structure to Formula C.
- R 1 is (i) a substituent containing a 5- or 6-membered cyclohydrocarbyl , heterocyclo, aryl or heteroaryl radical bonded directly to the depicted SO2 -group and having a length greater than about that of a hexyl group and less than about that of an eicosyl group, said R 1 defining a three-dimensional volume, when rotated about an axis drawn through the S ⁇ 2-bonded 1-position and the 4-position of a 6- membered ring radical or drawn through the SO2 -bonded 1-position and the center of 3,4-bond of a 5-membered ring radical, whose widest dimension in a direction transverse to the axis of rotation is about that of one furanyl ring to about that of two phenyl rings .
- Rl is an -NR 7 R8 group in which R 7 and R° are independently selected from the group consisting of hydrido, hydrocarbyl, aryl, substituted aryl, arylhydrocarbyl , and substituted arylhydrocarbyl .
- R 7 and R 8 are independently selected from the group consisting of a hydrido, alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, R a oxyalkyl , cycloalkyl, cycloalkylalkyl , aryl, arylalkyl, heteroaryl, heteroarylalkyl , and a heterocyclo substituent, each of which substituent groups is optionally substituted with an -A-R-E-Y substituent; in such an -A-R-E-Y substituent, A is selected from the group consisting of
- R is directly bonded to R 7 or R 8 , or both R 7 and R 8 ;
- the moiety R is selected from the group consisting of alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, heterocycloalkyl, cycloalkylalkyl , cycloalkoxyalkyl , heterocycloalkoxyalkyl , aryloxyalkyl , heteroaryloxyalkyl , arylthioalkyl , heteroarylthioalkyl , cycloalkylthioalkyl , and a heterocycloalkylthioalkyl group wherein the aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent is (i) unsubstituted or (ii) substituted with one or two radicals selected from the group consisting of a halo, alkyl,
- E is absent and R is bonded directly to Y; and the moiety Y is absent or is selected from the group consisting of a hydrido, alkyl, alkoxy, haloalkyl, aryl, aralkyl, cycloalkyl, heteroaryl, hydroxy, nitrile, nitro, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyl, R a oxyalkyl, perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl , alkenyl, heterocycloalkyl, cycloalkyl, trifluoromethyl , alkoxycarbonyl, and a aminoalkyl group, wherein the aryl, heteroaryl, aralkyl or heterocycloalkyl group is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of an alkanoyl , halo,
- G is a N-heterocyclo group; the substituent A is selected from the group consisting of
- A is absent and R is directly bonded to the N-heterocyclo group, G; the moiety R is selected from the group consisting of alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, heterocycloalkoxyalkyl , aryloxyalkyl , heteroaryloxyalkyl , arylthioalkyl , heteroarylthioalkyl , cycloalkylthioalkyl , and a heterocycloalkylthioalkyl group wherein the aryl or heteroaryl or cycloalkyl or heterocycloalkyl substituent is (i) unsubstituted or (ii) substituted with one or two radicals selected from the group consisting of a halo, alkyl, perfluoro
- E is absent and R is bonded directly to Y; and the moiety Y is absent or is selected from the group consisting of a hydrido, alkyl, alkoxy, haloalkyl, aryl, aralkyl, cycloalkyl, heteroaryl, hydroxy, nitrile, nitro, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyl, R a oxyalkyl, perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl, alkenyl, heterocycloalkyl, cycloalkyl, trifluoromethyl , alkoxycarbonyl, and a aminoalkyl group, wherein the aryl, heteroaryl, aralkyl or heterocycloalkyl group is (i) unsubstit
- R 7 and R 8 taken together with the nitrogen atom to which they are bonded; i.e., a -NR 7 R 8 group, form a group -G-A-R-E-Y wherein
- G is a N-heterocyclo group; the substituent A is selected from the group consisting of (1) -0-;
- R is selected from the group consisting of alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, heterocycloalkoxyalkyl , aryloxyalkyl , heteroaryloxyalkyl , arylthioalkyl , heteroarylthioalkyl , cycloalkylthioalkyl , and a heterocycloalkylthioalkyl group wherein the aryl or heteroaryl or cycloalkyl or heterocycloalkyl substituent is (i) unsubstituted or (ii) substituted with one or two radicals selected from the group consisting of a halo
- E is absent and R is bonded directly to Y; and the moiety Y is absent or is selected from the group consisting of a hydrido, alkyl, alkoxy, haloalkyl, aryl, aralkyl, cycloalkyl, heteroaryl, hydroxy, nitrile, nitro, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyl, R a oxyalkyl , perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl , alkenyl, heterocycloalkyl, cycloalkyl, trifluoromethyl , alkoxycarbonyl, and a aminoalkyl group, wherein the aryl, heteroaryl, aralkyl or heterocycloalkyl group is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of an alkanoyl, halo,
- Substituents R * ⁇ and R ⁇ are independently selected from the group consisting of a hydrido, alkyl, cycloalkyl, acylalkyl, halo, nitro, hydroxyl, cyano, alkoxy, haloalkyl, haloalkyloxy, hydroxyalkyl, a R ⁇ R c aminoalkyl substituent, thiol (-SH), alkylthio, arylthio, cycloalkylthio, cycloalkkoxy, alkoxyalkoxy, perfluoroalkyl , haloalkyl, heterocyclooxy and a
- R * °R c aminoalkyloxy substituent or R 5 and R 6 together with the atoms to which they are bonded form a further aliphatic or aromatic carbocyclic or heterocyclic ring having 5- to 7 -members.
- a R 20 group is (a) -O-R 21 , where R 21 is selected from the group consisting of a hydrido, C- ⁇ _-Cg-alkyl , aryl, ar-C- ⁇ -Cg-alkyl group and a pharmaceutically
- R 22 is a selectively removable protecting group such as a 2- tetrahydropyranyl , benzyl, p-methoxybenzyl , C- ⁇ -Cg- alkoxycarbonyl , trisubstituted silyl group or o- nitrophenyl group, peptide systhesis resin and the like, wherein the trisubstituted silyl group is substituted with C ] _-Cg-alkyl , aryl, or ar-C ⁇ -Cg-alkyl or a mixture thereof, and R 3 is a hydrido, C ] _-Cg- alkyl or benzyl group, (c) -NR13-0-R 14 , where Rl3 is as before and R 4 is hydrido, a pharmaceutically acceptable cation or C(V)R 15 where V is O (oxo) or S
- R 15 is selected from the group consisting of an C-L-C -alkyl , aryl, C- ⁇ -Cg-alkoxy, heteroaryl -C ⁇ ⁇ -C -alkyl , C3-C 8 -cycloalkyl-C-L-C -alkyl , aryloxy, ar-C- j _-C -alkoxy, ar-C- j _-Cg-alkyl , heteroaryl and amino C- [ _-Cg-alkyl group wherein the amino C- ⁇ -Cg- alkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two substituents independently selected from the group consisting of an C-L-Cg-alkyl, aryl, ar-C- j ⁇ -Cg-alkyl , C 3 -C 8 - cycloalkyl-C-
- R a is selected from the group consisting of a hydrido, alkyl, alkenyl, alkenyl, arylalkyl, aryl, alkanoyl, aroyl , arylalkycarbonyl , RbR c aminoalkanoyl , haloalkanoyl ,
- R-b and R c are independently selected from the group consisting of a hydrido, alkanoyl, arylalkyl, aroyl, bisalkoxyalkyl , alkyl, haloalkyl, perfluoroalkyl , trifluoromethylalkyl , perfluoroalkoxyalkyl , alkoxyalkyl, cycloalkyl, heterocycloalkyl, heterocycloalkylcarbonyl , aryl, heterocyclo, heteroaryl, cycloalkylalkyl, aryloxyalkyl , heteroaryloxyalkyl , heteroarylalkoxyalkyl , heteroarylthioalkyl , arylsulfonyl , aralkanoyl, alkylsulfonyl , heteroarylsulfonyl , carboxyalkyl , alkoxycarbonylalkyl , aminocarbonyl , alkylim
- R9 is selected from the group consisting of a hydrido, aryl, heteroaryl, heterocyclo, aroyl, alkanoyl, heteroaroyl, halogen (F, Cl , Br, I), cyano, aldehydo (CHO, formyl) , hydroxy, amino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl , alkoxy, aryloxy, heteroaryloxy, alkenyloxy, alkynyloxy, alkoxyaryl, alkoxyheteroaryl , R ⁇ R 1 -amino, alkoxyalkyl, alkylenedioxy, aryloxyalkyl , perfluoroalkyl , trifluoroalkyl , alkylthio, arylthio, alkyloxycarbonyl , alkyloxycarbonyloxy, aryloxycarbonyl , arylalkyloxy
- R" is selected from the group consisting of an arylalkyl, aryl, heteroaryl, heterocyclo, alkyl, alkynyl, alkenyl, alkoxyalkyl, alkoxyalkyl, substituted or unsubstituted aminoalkyl, alkyloxycarbonyl, arylalkyloxycarbonyl, carboxyalkyl, haloalkyl, alkanoyl, aroyl, substituted or unsubstituted aminoalkanoyl , halo alkanoyl and a hydroxyalkyl group, each of which groups is optionally substituted by one or two groups independently selected from RU substituents as are the substituents of the substituted aminoalkyl and substituted aminoalkanoyl groups; R 1 is selected from the group consisting of an arylalkyl, aryl, heteroaryl, heterocyclo, alkyl, alkynyl, alkenyl, alkoxyalkyl, alkoxyal
- Rl is selected from the group consisting of an arylalkyl, aryl, heteroaryl, heterocyclo, alkyl, alkynyl, alkenyl, alkoxyalkyl, alkoxyalkyl, substituted or unsubstituted aminoalkyl, alkyloxycarbonyl, arylalkyloxycarbonyl, carboxyalkyl, haloalkyl, alkanoyl, aroyl, substituted or unsubstituted aminoalkanoyl, halo alkanoyl and a hydroxyalkyl group, wherein the substituents of the substituted aminoalkyl and substituted aminoalkanoyl groups are selected from the group consisting of an alkyl, alkenyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl , aryloxycarbonyl and an alkyloxycarbonyl group; and R k is selected from hydrido, alkyl
- R c R ⁇ aminoalkanoyl and R c R ⁇ aminoalkysulfonyl .
- R ⁇ and R 6 are independently selected from the group consisting of hydrido, hydrocarbyl, preferably C1-C4 hydrocarbyl, hydroxylhydrocarbyl , hydroxyl, amino, dihydrocarbylamino, heterocyclo, heterocyclohydrocarbyl , heterocyclooxy, and heterocyclothio .
- the 5- or 6- membered aromatic or heteroaromatic ring W is a 1,2- phenylene, 2 , 3 -pyridinylene, 3 , 4 -pyridinylene, 4,5- pyridinylene, 2 , 3 -pyrazinylene, 4 , 5-pyrimidinylene, or 5 , 6-pyrimidinylene group.
- R20 s -NR13-0-R 22 are particularly preferred embodiements, R20 i s -NHOH so that a compound of Formula C corresponds in structure to Formula Cl
- a contemplated compound corresponds in structure to Formula C2 ,
- a R 4 substituent can be a single-ringed cyclohydrocarbyl, heterocyclo, aryl such as phenyl or heteroaryl group or another substituent having a chain length of 3 to about 14 carbon atoms such as a hydrocarbyl or hydrocarbyloxy group [e.g., C3-C1 4 hydrocarbyl or 0-C 2 -C ⁇ 4 hydrocarbyl] , a phenoxy group [-OCg ⁇ ] , a thiophenoxy group [phenylsulfanyl ; -SC H5] , an anilino group
- a contemplated compound corresponds in structure to Formula VI -1 wherein each of R 5 , R 6 , R 7 , R 8 and R 2 0 i s as defined before and each of A, B, C and D is carbon, nitrogen, sulfur or oxygen and is present or absent so that the depicted ring has 5- or 6-members.
- compound of one of the above formulas such as Formula C or Cl is a hydroxamate that is a selective inhibitor of MMP-2 over MMP-1 and usually also over MMP-13. That is, a hydroxamate compound of one of the formulas such as Formula C or Cl exhibits greater activity in inhibiting MMP-2 than in inhibiting MMP-1 and usually also MMP-13.
- R 20 is other than NH-OH, a compound of Formula VI -1 can be a precursor, pro-drug or active carboxylate as is the compound of Example 13.
- a particularly preferred embodiment of this aspect is a compound that corresponds in structure to Formulas VIA or VIA-1
- R 2 0, R 4 , R5 an ⁇ : 6 are as defined before and ring structure 2 including the depicted nitrogen atom is a heterocylic ring that contains 5- or 6-members, and R 4 is bonded at the 4 -position relative to that depicted nitrogen atom when w2 is a 6 -membered ring and at the 3- or 4 -position relative to that depicted nitrogen when W 2 is a 5-membered ring .
- Another particularly preferred embodiment of this aspect is a compound that corresponds in structure to Formulas VIB, VIB-1, VIB-2 or VIB-3
- a particularly preferred group of compounds of this class are the compounds whose structure corresponds to Formula D
- a process for treating a host mammal having a condition associated with pathological matrix metalloprotease activity comprises administering to a mammalian host having such a condition a compound corresponding in structure to Formula C, such as a conpound corresponding in styructure to Formula Cl, below, or a salt of such a compound, that selectively inhibits one or more MMPs, while exhibiting less activity against at least MMP-1 in an MMP enzyme- inhibiting effective amount.
- a contemplated compound also does not substantially inhibit the production of TNF.
- a benefit of this invention is the provision of a compound and composition effective for inhibiting metalloproteinases, particularly MMP-13 and/or MMP-2, associated with pathological conditions such as, for example, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal , epidermal or gastric ulceration, tumor metastasis, invasion or angiogenesis, periodontal disease, proteinuria, Alzheimer's Disease, coronary thrombosis, plaque formation and bone disease.
- pathological conditions such as, for example, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal , epidermal or gastric ulceration, tumor metastasis, invasion or angiogenesis, periodontal disease, proteinuria, Alzheimer's Disease, coronary thrombosis, plaque formation and bone disease.
- An advantage of the invention is the provision of a method for preparing such compounds and compositions. Another benefit is the provision of a method for treating a pathological condition associated with abnormal matrix metalloproteinase activity.
- Another advantage of the invention is the provision of compounds, compositions and methods effective for treating such pathological conditions by selective inhibition of a metalloproteinase such as MMP-13 and MMP-2 associated with such conditions with minimal side effects resulting from inhibition of other proteinases such as MMP-1, whose activity is necessary or desirable for normal body function.
- a metalloproteinase such as MMP-13 and MMP-2 associated with such conditions with minimal side effects resulting from inhibition of other proteinases such as MMP-1, whose activity is necessary or desirable for normal body function.
- certain sulfonyl aryl or heteroaryl hydroxamic acids are effective, inter alia, for inhibition of matrix metalloproteinases ("MMPs") believed to be associated with uncontrolled or otherwise pathological breakdown of connective tissue.
- MMPs matrix metalloproteinases
- these certain sulfonyl aryl or heteroaryl hydroxamic acid compounds are effective for inhibition of collagenase III (MMP-13) and also gelatinase A (MMP-2), which can be particularly destructive to tissue if present or generated in abnormal quantities or concentrations, and thus exhibit a pathological activity.
- One embodiment of the present invention is directed to a sulfonyl aryl or heteroaryl hydroxamic acid compound, a pharmaceutically acceptable salt of such a compound that can act as a matrix metalloprotease enzyme inhibitor, a precursor to such a compound or a pro-drug form of such a compound.
- a contemplated compound corresponds in structure to Formula C.
- ring structure W is a 5- or 6-membered aromatic or heteroaromatic ring;
- R**-- is (i) a substituent containing a 5- or
- the R--*- group defining a three- dimensional volume, when rotated about an axis drawn through the S0 2 -bonded 1-position and the 4-position of a 6 -membered ring radical or drawn through the S0 2 -bonded 1-position and the center of 3,4-bond of a 5-membered ring radical, whose widest dimension in a direction transverse to the axis of rotation is about that of one furanyl ring to about that of two phenyl rings.
- a R 1 group is (ii) an -NR 7 R 8 group in which R 7 and R 8 are independently selected from the group consisting of hydrido, hydrocarbyl, aryl, substituted aryl, arylhydrocarbyl, and substituted arylhydrocarbyl .
- a R 1 group is an -NR 7 R 8 group in which R 7 and R 8 are independently selected from the group consisting of a hydrido, alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, R a oxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and a heterocyclo substituent, each of which substituent groups is optionally substituted with an -A-R-E-Y substituent ; in such an -A-R-E-Y substituent, A is selected from the group consisting of
- R is directly bonded to R 7 or R 8 , or both R 7 and R 8 ;
- the moiety R is selected from the group consisting of alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, heterocycloalkoxyalkyl , aryloxyalkyl , heteroaryloxyalkyl , arylthioalkyl , heteroarylthioalkyl , cycloalkylthioalkyl , and a heterocycloalkylthioalkyl group wherein the aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent is (i) unsubstituted or (ii) substituted with one or two radicals selected from the group consisting of a halo, alkyl,
- E is absent and R is bonded directly to Y; and the moiety Y is absent or is selected from the group consisting of a hydrido, alkyl, alkoxy, haloalkyl, aryl, aralkyl, cycloalkyl, heteroaryl, hydroxy, nitrile, nitro, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyl, R a oxyalkyl , perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl , alkenyl, heterocycloalkyl, cycloalkyl, trifluoromethyl , alkoxycarbonyl, and a aminoalkyl group, wherein the aryl, heteroaryl, aralkyl or heterocycloalkyl group is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of an alkanoyl, halo,
- R 7 and R 8 taken together with the nitrogen atom to which they are bonded (-NR 7 R 8) form a group -G-A-R-E-Y wherein
- G is a N-heterocyclo group; the substituent A is selected from the group consisting of
- R is directly bonded to the N-heterocyclo group, G.
- the moiety R is selected from the group consisting of alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, heterocycloalkoxyalkyl , aryloxyalkyl , heteroaryl - oxyalkyl, arylthioalkyl , heteroarylthioalkyl , cycloalkylthioalkyl , and a heterocycloalkylthioalkyl group wherein the aryl or heteroaryl or cycloalkyl or heterocycloalkyl substituent is (i) unsubstituted or (ii) substituted with one or two radicals selected from the group consisting of a halo, alkyl, perfluoride,
- the moiety E is selected from the group consisting of (1) -C0R9- or -R9C0- ;
- E is absent and R is bonded directly to Y; and the moiety Y is absent or is selected from the group consisting of a hydrido, alkyl, alkoxy, haloalkyl, aryl, aralkyl, cycloalkyl, heteroaryl, hydroxy, nitrile, nitro, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyl, R a oxyalkyl, perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl , alkenyl, heterocycloalkyl, cycloalkyl, trifluoromethyl , alkoxycarbonyl, and a aminoalkyl group, wherein the aryl, heteroaryl, aralkyl or heterocycloalkyl group is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of an alkanoyl, halo,
- R5 and R ⁇ are independently selected from the group consisting of a hydrido, alkyl, cycloalkyl, acylalkyl, halo, nitro, hydroxyl, cyano, alkoxy, haloalkyl, haloalkyloxy, hydroxyalkyl, and a
- R a is selected from the group consisting of a hydrido, alkyl, alkenyl, alkenyl, arylalkyl, aryl, alkanoyl, aroyl, arylalkycarbonyl , R ⁇ R C aminoalkanoyl , haloalkanoyl,
- R 3 and R c are independently selected from the group consisting of a hydrido, alkanoyl, arylalkyl, aroyl, bisalkoxyalkyl , alkyl, haloalkyl, perfluoroalkyl , trifluoromethylalkyl , perfluoroalkoxyalkyl , alkoxyalkyl, cycloalkyl, heterocycloalkyl, heterocycloalkylcarbonyl , aryl, heterocyclo, heteroaryl, cycloalkylalkyl, aryloxyalkyl , heteroaryloxyalkyl , heteroarylalkoxyalkyl , heteroarylthioalkyl , arylsulfonyl, aralkanoyl, alkylsulfonyl , heteroarylsulfonyl , carboxyalkyl , alkoxycarbonylalkyl , aminocarbonyl , alkylimino
- R ⁇ and R e are independently selected from the group consisting of a hydrido, alkyl, alkenyl, alkenyl, arylalkyl, aryl, alkanoyl, aroyl, arylalkycarbonyl , alkoxycarbonyl or arylalkyloxycarbonyl group;
- R-f is selected from the group consisting of a nitro, hydroxy, alkyl, halogen (halo; F, Cl, Br,
- R9 is selected from the group consisting of a hydrido, aryl, heteroaryl, heterocyclo, aroyl, alkanoyl, heteroaroyl, halogen (F, Cl , Br, I), cyano, aldehydo (CHO, formyl), hydroxy, amino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl , alkoxy, aryloxy, heteroaryloxy, alkenyloxy, alkynyloxy, alkoxyaryl, alkoxyheteroaryl , R ⁇ R 1 -amino, alkoxyalkyl, alkylenedioxy, aryloxyalkyl , perfluoroalkyl , trifluoroalkyl , alkylthio, arylthio, alkyloxycarbonyl , alkyloxycarbonyloxy, aryloxycarbonyl , arylalkyloxycarbony
- R- ⁇ R 1 -aminoalkanoyl hydroxyaminocarbonyl , R ⁇ R 1 - aminosulfonyl , R ⁇ R 1 -aminocarbonyl (R") amino, trifluoromethylsulfonyl (R n ) amino, heteroarylsulfonyl- (Rh) amino, arylsulfonyl (R n ) amino, arylsulfonyl (R n ) - aminocarbonyl , alkylsulfonyl (R-”) amino, arylcarbonyl-
- R-h is selected from the group consisting of an arylalkyl, aryl, heteroaryl, heterocyclo, alkyl, alkynyl , alkenyl , alkoxyalkyl , alkoxyalkyl , substituted or unsubstituted aminoalkyl, alkyloxycarbonyl, arylalkyloxycarbonyl, carboxyalkyl, haloalkyl, alkanoyl, aroyl, substituted or unsubstituted aminoalkanoyl, halo alkanoyl and a hydroxyalkyl group, each of which groups is optionally substituted by one or two groups. independently selected from Rl substituents as are the substituents of the substituted aminoalkyl and substituted aminoalkanoyl groups;
- R 1 is selected from the group consisting of an arylalkyl, aryl, heteroaryl, heterocyclo, alkyl, alkynyl, alkenyl, alkoxyalkyl, alkoxyalkylalkyl , substituted or unsubstituted aminoalkyl, alkyloxycarbonyl, arylalkyloxycarbonyl, carboxyalkyl, haloalkyl, alkanoyl, aroyl, substituted or unsubstituted aminoalkanoyl, halo alkanoyl and a hydroxyalkyl group, each of which groups are optionally substituted by one or two Rl substituents;
- Rl is selected from the group consisting of an arylalkyl, aryl, heteroaryl, heterocyclo, alkyl, alkynyl, alkenyl, alkoxyalkyl, alkoxyalkyl, substituted or unsubstituted aminoalkyl, alkyloxycarbonyl, arylalkyloxycarbonyl, carboxyalkyl, haloalkyl, alkanoyl, aroyl, substituted or unsubstituted aminoalkanoyl, halo alkanoyl and a hydroxyalkyl group, wherein the substituents of the substituted aminoalkyl and substituted aminoalkanoyl groups are selected from the group consisting of an alkyl, alkenyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryloxycarbonyl and an alkyloxycarbonyl group; and
- R k is selected from hydrido, alkyl, alkenyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryloxycarbonyl, alkyloxycarbonyl,
- R c R ⁇ amino carbonyl R c R ⁇ aminosulfonyl , R c R"aminoalkanoyl and R c R ⁇ aminoalkysulfonyl .
- R 20 is (a) -O-R 21 , where R 21 is selected from the group consisting of a hydrido, C- ⁇ -Cg-alkyl, aryl, ar-C-
- R 22 is a selectively removable protecting group such as a 2- tetrahydropyranyl , benzyl, p-methoxybenzyl (MOZ) , C- j _- C -alkoxycarbonyl, trisubstituted silyl group or o- nitrophenyl group, peptide systhesis resin and the like, wherein the trisubstituted silyl group is substituted with C ] _-Cg-alkyl , aryl, or ar-C ] _-Cg-alkyl or a mixture thereof, and R 3 is a hydrido, C]_-Cg- alkyl or benzyl group, (c) -NRl3-0-R 14 , where R 3 is as before and R *** - 4 is hydrido, a pharmaceutically acceptable cation or C(V)R 1: ⁇ where V is O
- R 15 is selected from the group consisting of an C- j _-Cg-alkyl , aryl, C- j _-C -alkoxy, heteroaryl-C- j ⁇ -Cg-alkyl , C3-Cg-cycloalkyl-C- [ _-Cg-alkyl , aryloxy, ar-C- ⁇ -Cg-alkoxy, ar-C- ⁇ -Cg-alkyl , heteroaryl and amino C- ⁇ -Cg-alkyl group wherein the amino C- ⁇ -Cg- alkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two substituents independently selected from the group consisting of an C- ⁇ -Cg-alkyl, aryl, ar-C- j _ -Cg -alkyl , C3-C3- cycloalkyl -C-
- a compound of Formula C embraces a useful precursor compound, a pro-drug form of a hydroxamate and the hydroxamate itself, as well as amide compounds that can be used as intermediates and also as MMP inhibitor compounds.
- R 20 is -0-R 21 , in which R 21 is selected from the group consisting of a hydrido, C- ⁇ Cg -alkyl, aryl, ar-
- a precursor carboxylic acid or ester is defined that can be readily transformed into a hydroxamic acid, as is illustrated in several
- Such a carboxyl compound that is a precursor to a hydroxamate can also have activity as an inhibitor of MMP enzymes as is seen from the Inhibition Table of those Examples.
- Another useful precursor compound is defined when R 20 is -NR 13 -0-R 22 , wherein R 22 is a selectively removable protecting group and R is a hydrido or benzyl group, preferably a hydrido group.
- a selectively removable protecting group is exemplified as a 2-tetrahydropyranyl , benzyl, p- methoxybenzyloxycarbonyl (MOZ) , benzyloxycarbonyl (BOC) , C x -Cg -alkoxycarbonyl, - , C ⁇ -
- a trisubstituted silyl group is a silyl group substituted with C- * *__-Cg -alkyl, aryl, or ar-C ⁇ -Cg-alkyl substituent groups or a mixture thereof such as a trimethylsilyl , triethylsilyl , dimethylisopropylsilyl , triphenylsilyl , t- butyldiphenylsilyl , diphenylmethylsilyl , a tribenzylsilyl group, and the like.
- a contemplated peptide synthesis resin is solid phase support also known as a so-called Merrifield's Peptide Resin that is adapted for synthesis and selective release of hydroxamic acid derivatives as is commercially available from Sigma Chemical Co., St. Louis , MO.
- An exemplary peptide synthesis resin so adapted and its use in the synthesis of hydroxamic acid derivatives is discussed in Floyd et al . , Tetrahedron Let . , 37 (44) :8048- 8048 (1996) .
- a 2-tetrahydropyranyl (THP) protecting group is a particularly preferred selectively removable protecting group and is often used when R- * - 3 is a hydrido group.
- a contemplated THP-protected hydroxamate compound of Formula A can be prepared by reacting the carboxylic acid precursor compound of
- R 20 is -O-R 21 and R 21 is a hydrido group
- O- (tetrahydro-2H-pyran-2- yl) hydroxylamine in the presence of N- methylmorpholine, N-hydroxybenzotriazole hydrate and a water-soluble carbodiimide such as l-(3- dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride .
- the resulting THP-protected hydroxamate corresponds in structure to Formula C3 , below, where W, R 1 , R 5 and R 6 are as defined previously and more fully hereinafter.
- the THP protecting group is readily removable in an aqueous acid solution such as an aqueous mixture of p- toluenesulfonic acid or HCl and acetonitrile or methanol .
- Another aspect of the invention contemplates a compound that corresponds in structure to Formula VI- 1, below,
- a hydroxamate compound of Formula VI -1 is a selective inhibitor of MMP-2 over both of MMP-1 and MMP-13. That is, a hydroxamate compound of Formula VI exhibits greater activity in inhibiting MMP-2 than in inhibiting either MMP-1 and usuallya also MMP-13.
- a particularly preferred embodiment of this aspect of the invention is a compound that corresponds in structure to Formulas VIA or VIA-1
- ring structure W 2 including the depicted nitrogen atom is a heterocylic ring that contains 5- or 6-members, and R 4 is bonded at the 4 -position relative to that depicted nitrogen atom when W 2 is a 6 -membered ring and at the 3- or 4 -position relative to that depicted nitrogen when w2 is a 5-membered ring.
- the ring structure W 2 is preferably a N- piperidinyl group that is itself preferably substituted as is discussed hereinafter.
- R 2 Q , R 5 , R 6 , R 7 , and R 8 are as defined before .
- a further embodiment of the present invention is directed to a sulfonyl aryl or heteroaryl hydroxamic acid compound that can act as a matrix metalloprotease enzyme inhibitor. That compound corresponds in structure to Formula C4
- the ring structure W is a 5- or 6 -membered aromatic or heteroaromatic ring
- R 1 is a substituent containing a 5- or 6- membered cyclohydrocarbyl, heterocyclo, aryl or heteroaryl radical bonded directly to the depicted S0 2 -group and having a length greater than about that of a hexyl group and less than about that of an eicosyl group, said R 1 defining a three-dimensional volume, when rotated about an axis drawn through the S0 2 -bonded 1-position and the 4-position of a 6- membered ring radical or drawn through the S0 2 -bonded
- R5 and R ⁇ are independently selected from the group consisting of a hydrido, alkyl, cycloalkyl, acylalkyl, halo, nitro, hydroxyl, cyano, alkoxy, haloalkyl, haloalkyloxy, hydroxyalkyl, a R*t ) R c aminoalkyl substituent, thiol, alkylthio, arylthio, cycloalkylthio, cycloalkkoxy, alkoxyalkoxy, perfluoroalkyl , haloalkyl, heterocyclooxy and a
- R ⁇ R c aminoalkyloxy substituent or R 5 and R° together with the atoms to which they are bonded form a further aliphatic or aromatic carbocyclic or heterocyclic ring having 5- to 7 -members.
- R 1 is an -NR 7 R 8 group in which R 7 and R 8 are independently selected from the group consisting of hydrido, hydrocarbyl, aryl, substituted aryl, arylhydrocarbyl, and subsituted arylhydrocarbyl.
- R and R 8 are independently selected from the group consisting of a hydrido, alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl,
- R a oxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and a heterocyclo substituent, each of which substituent groups is optionally substituted with an -A-R-E-Y substituent; in such an -A-R-E-Y substituent, A is selected from the group consisting of
- R is directly bonded to R 7 or R 8 , or both R 7 and R 8 ;
- the moiety R is selected from the group consisting of alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, heterocycloalkoxyalkyl , aryloxyalkyl , heteroaryloxyalkyl , arylthioalkyl , heteroarylthioalkyl , cycloalkylthioalkyl , and a heterocycloalkylthioalkyl group wherein the aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent is (i) unsubstituted or (ii) substituted with one or two radicals selected from the group consisting of a halo, alkyl,
- E is absent and R is bonded directly to Y; and the moiety Y is absent or is selected from the group consisting of a hydrido, alkyl, alkoxy, haloalkyl, aryl, aralkyl, cycloalkyl, heteroaryl, hydroxy, nitrile, nitro, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyl, R a oxyalkyl, perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl , alkenyl, heterocycloalkyl, cycloalkyl, trifluoromethyl , alkoxycarbonyl, and a aminoalkyl group, wherein the aryl, heteroaryl, aralkyl or heterocycloalkyl group is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of an alkanoyl, halo,
- R 7 and R 8 taken together with the nitrogen atom to which they are bonded (-
- NR 7 R 8 form a group -G-A-R-E-Y wherein G is a N-heterocyclo group; the substituent A is selected from the group consisting of
- R is selected from the group consisting of alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, heterocycloalkoxyalkyl , aryloxyalkyl , heteroaryloxyalkyl , arylthioalkyl , heteroaryl - thioalkyl, cycloalkylthioalkyl , and a heterocycloalkylthioalkyl group wherein the aryl or heteroaryl or cycloalkyl or heterocycloalkyl substituent is (i) unsubstituted or (ii) substituted with one or two radicals selected from the group consisting of a
- E is absent and R is bonded directly to Y; and the moiety Y is absent or is selected from the group consisting of a hydrido, alkyl, alkoxy, haloalkyl, aryl, aralkyl, cycloalkyl, heteroaryl, hydroxy, nitrile, nitro, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyl, R a oxyalkyl, perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl , alkenyl, heterocycloalkyl, cycloalkyl, trifluoromethyl , alkoxycarbonyl, and a aminoalkyl group, wherein the aryl, heteroaryl, aralkyl or heterocycloalkyl group is (i) unsubstitute
- R * ⁇ and R" are independently selected from the group consisting of a hydrido, hydrocarbyl, preferably C1-C4 hydrocarbyl, hydroxylhydrocarbyl , hydroxyl, amino,
- R * ⁇ and R° are independently selected from the group consisting of a hydrido, alkyl, cycloalkyl, acylalkyl, halo, nitro, hydroxyl, cyano, alkoxy, haloalkyl, haloalkyloxy, hydroxyalkyl, and a R*kR c aminoalkyl substituent .
- Contemplated aromatic or heteroaromatic rings include 1 , 2 -phenylene, 2 , 3-pyridinylene, 3,4- pyridinylene, 4 , 5-pyridinylene, 2 , 3-pyrazinylene, 4 , 5-pyrimidinylene, and 5, 6-pyrimidinylene groups.
- 1 , 2 -Phenylene ( a 1 , 2-disubstituted phenyl ring) is a particularly preferred aromatic or heteroaromatic ring, and is used illustratively herein as W.
- an R 1 substituent contains a 5- or 6-membered cyclohydrocarbyl, heterocyclo, aryl or heteroaryl radical bonded directly to the depicted S0 -group.
- An R 1 substituent also has length, width and substitution requirements that are discussed in detail below. It is noted here, however, that a single- ringed or fused ring cyclohydrocarbyl , heterocyclo, aryl or heteroaryl radical is not itself long enough to fulfill the length requirement for a preferred compound, particularly where R 1 is NR 7 R 8 . As such, that cyclohydrocarbyl, heterocyclo, aryl or heteroaryl radical should itself be substituted.
- Exemplary 5- or 6 -membered cyclohydrocarbyl, heterocyclo, aryl or heteroaryl radicals that can constitute a portion of a R 1 substituent and are themselves substituted as discussed herein include phenyl, 2-, 3-, or 4- pyridyl, 2-naththyl, 2 -pyrazinyl, 2- or 5- pyrimidinyl , 2- or 3 -benzo (b) thienyl , 8-purinyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-imidazolyl , cyclopentyl, cyclohexyl, 2- or 3 -piperidinyl , 2- or 3-morpholinyl , 2- or 3-tetrahydropyranyl , 2- imidazolidinyl , 2- or 3-pyrazolidinyl and the like.
- a phenyl radical is particularly preferred and is used illustratively herein.
- an R 1 substituent (including NR 7 R 8 as an R 1 substituent) , including its own substituent when present, has a total length equivalent to a length that is greater than that of a fully extended saturated chain of six carbon atoms (a hexyl group) ; i.e., a length of a heptyl chain in staggered conformation or longer, and a length that is less than that of a fully extended saturated chain of about 20 carbons (an eicosyl group) .
- That length is about 8 to about 18 carbon atoms, even though many more atoms may be present in ring structures or substituents. This length requirement is discussed further below.
- an R ⁇ substituent radical, group or moiety
- Such an R 1 substituent also has a length that is less than that of an eicosyl group.
- a R 1 is a substituent having a length greater than that of a fully extended saturated six carbon chain and shorter than that of a fully extended saturated twenty carbon chain, and more preferably, a length greater than that of a octyl group and less than that of a palmityl group.
- the radical chain lengths are measured along the longest linear atom chain in the radical, following the skeletal atoms of a ring where necessary. Each atom in the chain, e.g. carbon, oxygen or nitrogen, is presumed to be carbon for ease in calculation.
- Such lengths can be readily determined by using published bond angles, bond lengths and atomic radii, as needed, to draw and measure a chain, or by building models using commercially available kits whose bond angles, lengths and atomic radii are in accord with accepted, published values. Radical (substituent) lengths can also be determined somewhat less exactly by presuming, as is done here, that all atoms have bond lengths of saturated carbon, that unsaturated and aromatic bonds have the same lengths as saturated bonds and that bond angles for unsaturated bonds are the same as those for saturated bonds, although the above-mentioned modes of measurement are preferred.
- a 4 -phenyl or 4 -pyridyl group has a length of a four carbon chain, as does a propoxy group, whereas a biphenyl group has a length of about an eight carbon chain using a contemplated measurement mode.
- an R-**- substituent when rotated about an axis drawn through the S0 2 -bonded 1-position and the 4-position of a 6-membered ring radical or the S0 2 -bonded 1-position and through the
- 3,4 bond of a 5-membered ring radical defines a three-dimensional volume whose widest dimension has the width of about one furanyl ring to about the width of two phenyl rings in a direction transverse to that axis to rotation.
- a fused ring system such as a naphthyl or purinyl radical is considered to be a 6- or 5- membered ring that is substituted at appropriate positions numbered from the S0 2 - linkage that is deemed to be at the 1-position as discussed before.
- a 2 -naphthyl substituent or an 8 -purinyl substituent is an appropriately sized R 1 radical as to width when examined using the above rotational width criterion.
- a 1 -naphthyl group or a 7- or 9-purinyl group is too large upon rotation and is excluded.
- 4- (picolinamido) phenyl and 4- (benzamido) phenyl are among particularly preferred R 1 substituents, with 4- (phenoxy) phenyl and 4- (thiophenyl) phenyl being most preferred.
- An S0 -linked cyclohydrocarbyl, heterocyclo, aryl or heteroaryl radical is a 5- or 6-membered single-ring that is itself substituted with one other substituent, R 4 .
- the S0 2 -linked single-ringed cyclohydrocarbyl, heterocyclo, aryl or heteroaryl radical is R 4 -substituted at its own 4-position when a 6-membered ring and at its own 3- or 4-position when a 5-membered ring.
- the cyclohydrocarbyl, heterocyclo, aryl or heteroaryl radical to which R 4 is bonded in some embodiments is preferably a phenyl group, so that R 1 is preferably
- a heterocyclo or heteroaryl radical is preferred over a phenyl radical, with the R 4 substituent being linked at the 4-position relative to the bond between the ring and the S0 2 group .
- R 4 substituent can be a single-ringed cyclohydrocarbyl, heterocyclo, aryl or heteroaryl group or another substituent having a chain length of 3 to about 14 carbon atoms such as a hydrocarbyl or hydrocarbyloxy group [e.g., C3-C14 hydrocarbyl or 0-C 2 -Ci4 hydrocarbyl], a phenyl group, a phenoxy group [-OCg ⁇ ] , a thiophenoxy group
- R 4 substituent groups include a heterocyclo, heterocyclohydrocarbyl , arylhydrocarbyl , arylheterocyclohydrocarbyl , heteroarylhydrocarbyl , heteroarylheterocyclo-hydrocarbyl , arylhydrocarbyloxyhydrocarbyl , aryloxyhydrocarbyl , hydrocarboylhydrocarbyl, arylhydrocarboylhydrocarbyl, arylcarbonylhydrocarbyl , arylazoaryl , arylhydrazinoaryl , hydrocarbyl -thiohydrocarbyl , hydrocarbylthioaryl , arylthiohydrocarbyl , heteroarylthiohydrocarbyl , hydrocarbylthioarylhydrocarbyl , arylhydrocarbyl - thiohydrocarbyl ,
- R 4 substituent can itself also be substituted with one or more substituent radicals at the meta- or para-position or both of a six-membered ring with a single atom or a substituent containing a longest chain of up to ten atoms, excluding hydrogen.
- substituent radicals include a halo, hydrocarbyl, hydrocarbyloxy, nitro, cyano, perfluorohydrocarbyl , trifluoromethyl - hydrocarbyl, hydroxy, mercapto, hydroxycarbonyl , aryloxy, arylthio, arylamino, arylhydrocarbyl, aryl, heteroaryloxy, heteroarylthio, heteroarylamino, heteroarhydrocarbyl , hydrocarbyloxycarbonyl - hydrocarbyl , heterocyclooxy, hydroxycarbonyl - hydrocarbyl, heterocyclothio, heterocycloamino, cyclohydrocarbylox , cyclohydrocarbylthio , cyclohydrocarbylamino, heteroarylhydrocarbyloxy, heteroarylhydrocarbylthio , heteroaryl - hydrocarbylamino, arylhydrocarbyloxy, arylhydrocarbyl
- a particularly preferred R 4 substituent of an S0 2 -linked Ph group is a single-ringed aryl or heteroaryl, phenoxy, thiophenoxy, phenylazo, phenylureido, nicotinamido, isonicotinamido, picolinamido, anilino or benzamido group that is unsubstituted or is itself substituted (optionally substituted) at the para-position when a 6-membered ring or the 3- or 4-position when a 5-membered ring.
- single atoms such as halogen moieties or substituents that contain one to a chain of about ten atoms other than hydrogen such as C]_-C]_Q hydrocarbyl, C ⁇ -Cg hydrocarbyloxy or carboxyethyl groups can be used.
- PhR 4 particularly preferred R 1 substituents include biphenyl, 4-phenoxyphenyl , 4-thiophenoxyphenyl , 4- benzamidophenyl , 4 -phenylureido, 4-anilinophenyl , 4- nicotinamido, 4 -isonicotinamido, and 4 -picolinamido .
- Exemplary particularly preferred R 4 groups contain a 6-membered aromatic ring and include a phenyl group, a phenoxy group, a thiophenoxy group, a phenylazo group, a phenylureido group, an anilino group, a nicotinamido group, an isonicotinamido group, a picolinamido group and a benzamido group.
- a particularly preferred sulfonyl butanhydroxamate compounds has an R 4 substituent that is a phenyl group, a phenoxy group, a thiophenoxy group, a phenylazo group, a phenylureido group, an anilino group, a nicotinamido group, an isonicotinamido group, a picolinamido group or a benzamido group that is itself optionally substituted at its own meta or para-position or both with a moiety that is selected from the group consisting of a halogen, a halohydrocarbyl group, a halo C ⁇ -Cg hydrocarbyloxy group, a perfluoro C1-C9 hydrocarbyl group, a C ⁇ -Cg hydrocarbyloxy (-O-C ⁇ -Cg hydrocarbyl) group, a hydrocarbyl group, a di- C ⁇ -Cg hydrocarbylamin
- the 1-position of an above-discussed SO2- linked cyclohydrocarbyl, heterocyclo, aryl or heteroaryl radical is the position at which the SO2- group is bonded to the ring.
- the 4- and 3 -positions of rings discussed here are numbered from the sites of substituent bonding from the SO2-linkage as compared to formalized ring numbering positions used in heteroaryl nomenclature.
- a contemplated compound corresponds in structure to Formula C2 , wherein W, R 5 , R 6 and R 14 are as defined above, Ph is phenyl substituted at the 4-position with substituent R 4 that is defined hereinabove.
- the length of a R 1 substituent bonded to the SO2 group is believed to play a role in the overall activity of a contemplated inhibitor compound against MMP enzymes generally.
- a compound having an R 1 substituent that is shorter in length than a heptyl group typically exhibits moderate to poor inhibitory activity against all of the MMP enzymes
- compounds whose Rl substituents have a length of about an heptyl chain or longer e.g., a 4- phenoxyphenyl group that has a length of about a nine-carbon chain, typically exhibit good to excellent potencies against MMP-13 or MMP-2 and also selectivity against MMP-1.
- Exemplary data are provided in the Inhibition Tables hereinafter in which the activities of the above two compounds can be compared .
- a contemplated compound corresponds in structure to Formula C4 , below,
- R 1 is preferably PhR 4 , as is also defined above.
- W be a 1, 2 -phenylene radical and the preference for R 1 being PhR 4
- particularly preferred compounds correspond in structure to Formulas VIB, VIB-1, VIB-2 VIB-3, VII, VII-B, VIIC, VIID, VIIE, VIII and, VIIIB, below, wherein the above definitions for -A-R-E-Y, -G-A-R-E-Y, W 2 , Rl , R5 , R6 f R 7 f R 8 anc j R20 a lso apply, and wherein the substituent -A-R-E-Y is bonded to ring structure W 2 or a depicted ring structure .
- the compound of Example 24 has a structure that corresponds to that of Formula D2.
- R 5 and R ⁇ are both methoxy
- the A moiety is a sulfur atom, -S-
- R is 1, 4 -phenylene
- E is absent and the moiety Y is hydrido.
- the compound of Example 25 also corresponds in structure to Formula D2.
- R 5 and R ⁇ are again both methoxy, the A moiety is an oxygen atom, -0-, R is 1 , 4 -phenylene, E is absent and the moiety Y is a dialkoxy-substituted phenyl (aryl) group.
- hydrocarbyl is used herein as a short hand term to include straight and branched chain aliphatic as well as alicyclic groups or radicals that contain only carbon and hydrogen.
- alkyl, alkenyl and alkynyl groups are contemplated, whereas aromatic hydrocarbons such as phenyl and naphthyl groups, which strictly speaking are also hydrocarbyl groups, are referred to herein as aryl groups or radicals, as discussed hereinafter.
- aryl groups or radicals as discussed hereinafter.
- a specific aliphatic hydrocarbyl substituent group is intended, that group is recited; i.e., C1-C4 alkyl, methyl or dodecenyl .
- Exemplary hydrocarbyl groups contain a chain of 1 to about 12 carbon atoms, and preferably one to about 10 carbon atoms.
- hydrocarbyl group is an alkyl group.
- a generalized, but more preferred substituent can be recited by replacing the descriptor "hydrocarbyl” with “alkyl” in any of the substituent groups enumerated herein.
- alkyl radicals examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like.
- suitable alkenyl radicals include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4- pentadienyl, 1 , 4-butadienyl , 1-butenyl, 2-butenyl, 3- butenyl, decenyl and the like.
- alkynyl radicals examples include ethynyl , 2-propynyl, 3-propynyl, decynyl, 1-butynyl, 2-butynyl, 3-butynyl, and the like.
- hydrocarbyl ether is referred to as a "hydrocarbyloxy” group rather than a "hydrocarboxy” group as may possibly be more proper when following the usual rules of chemical nomenclature.
- hydrocarbyl group containing a -C(0)0- functionality is referred to as a hydrocarboyl group inasmuch as there is no ambiguity in using that suffix.
- a substituent that cannot exist such as a C ] _ alkenyl group is not intended to be encompassed by the word “hydrocarbyl” .
- thiol or “sulfhydryl " , alone or in combination, means a -SH group.
- thio or "thia”, alone or in combination, means a thiaether group; i.e., an ether group wherein the ether oxygen is replaced by a sulfur atom, as in a thiophenoxy group (C5H5-S-) .
- amino alone or in combination, means an amine or -NH2 group
- mono- substituted amino alone or in combination, means a substituted amine -N(H) (substituent) group wherein one hydrogen atom is replaced with a substituent
- disubstituted amine means a -N (substituent ) 2 wherein two hydrogen atoms of the amino group are replaced with independently selected substituent groups.
- Amines, amino groups and amides are classes that can be designated as primary (1°), secondary (11°) or tertiary (111°) or unsubstituted, mono-substituted or di-substituted depending on the degree of substitution of the amino nitrogen.
- Quaternary amine (IV°) means a nitrogen with four substituents [-N + (substituent) 4] that is positively charged and accompanied by a counter ion or N-oxide means one substituent is oxygen and the group is represented as
- hydroxyl alone or in combination, means a -OH group.
- nitro alone or in combination, means a -NO2 group.
- hydrazino alone or in combination, means a -NH-NH- group wherein the remaining two bonds (valences) are independently substituted.
- the hydrogen atoms of the hydrazino group can be replaced, independently, with substituents and the nitrogen atoms can form acid addition salts or be quaternized.
- sulfonyl alone or in combination, means a -S(0)2- group wherein the remaining two bonds (valences) can be independently substituted.
- hydrocarbyloxy means an hydrocarbyl ether radical wherein the term hydrocarbyl is as defined above.
- suitable hydrocarbyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, allyloxy, n-butoxy, iso-butoxy, sec-butoxy, tert- butoxy and the like.
- cyclohydrocarbyl alone or in combination, means a hydrocarbyl radical that contains 3 to about 8 carbon atoms, preferably from about 3 to about 6 carbon atoms, and is cyclic.
- cyclohydrocarbylhydrocarbyl means an hydrocarbyl radical as defined above which is substituted by a cyclohydrocarbyl as also defined above.
- examples of such cyclohydrocarbylhydrocarbyl radicals include cyclopropyl, cyclobutyl, cyclopentenyl, cyclohexyl cyclooctynyl and the like.
- aryl alone or in combination, means a phenyl or naphthyl radical that optionally carries one or more substituents selected from hydrocarbyl, hydrocarbyloxy, halogen, hydroxy, amino, nitro and the like, such as phenyl, p-tolyl, 4- methoxyphenyl , 4- (tert-butoxy) phenyl , 4-fluorophenyl , 4-chlorophenyl , 4-hydroxyphenyl , and the like.
- arylhydrocarbyl alone or in combination, means an hydrocarbyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, 2- phenylethyl and the like.
- arylhydrocarbyloxycarbonyl alone or in combination, means a radical of the formula -C(0)-0- arylhydrocarbyl in which the term “arylhydrocarbyl” has the significance given above.
- An example of an arylhydrocarbyloxycarbonyl radical is benzyloxycarbonyl .
- aryloxy means a radical of the formula aryl-O- in which the term aryl has the significance given above.
- aromatic ring in combinations such as substituted-aromatic ring sulfonamide, substituted-aromatic ring sulfinamide or substituted-aromatic ring sulfenamide means aryl or heteroaryl as defined above.
- hydrocarbyloyl or “hydrocarbylcarbonyl” , alone or in combination, mean an acyl radical derived from an hydrocarbylcarboxylic acid, examples of which include acetyl, propionyl , acryloyl, butyryl, valeryl, 4-methylvaleryl, and the like.
- cyclohydrocarbylcarbonyl means an acyl group derived from a monocyclic or bridged cyclohydrocarbylcarboxylic acid such as cyclopropanecarbonyl , cyclohexenecarbonyl , adamantanecarbonyl , and the like, or from a benz- fused monocyclic cyclohydrocarbylcarboxylic acid that is optionally substituted by, for example, a hydrocarbyloylamino group, such as 1,2,3,4- tetrahydro-2-naphthoyl , 2-acetamido-l ,2,3,4- tetrahydro-2-naphthoyl .
- arylhydrocarbyloyl or “arylhydrocarbylcarbonyl” mean an acyl radical derived from an aryl-substituted hydrocarbylcarboxylic acid such as phenylacetyl, 3- phenylpropenyl (cinnamoyl) , 4-phenylbutyryl , (2- naphthyl) acetyl , 4-chlorohydrocinnamoyl , 4- aminocinnamoyl , 4 -methoxycinnamoyl and the like.
- aroyl or arylcarbonyl means an acyl radical derived from an aromatic carboxylic acid.
- radicals include aromatic carboxylic acids, an optionally substituted benzoic or naphthoic acid such as benzoyl , 4-chlorobenzoyl , 4-carboxybenzoyl , 4- (benzyloxycarbonyl) benzoyl , 2- naphthoyl , 6-carboxy-2 naphthoyl , 6-
- heterocyclyl (heterocyclo) or heterocyclohydrocarbyl portion of a heterocyclylcarbonyl , heterocyclyloxycarbonyl , heterocyclylhydrocarbyloxycarbonyl , or heterocyclohydrocarbyl group or the like is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle that contains one to four hetero atoms selected from nitrogen, oxygen and sulphur, which is optionally substituted on one or more carbon atoms by a halogen, alkyl, alkoxy, oxo group, and the like, and/or on a secondary nitrogen atom (i.e., -NH-) by an hydrocarbyl, arylhydrocarbyloxycarbonyl, hydrocarbyloyl , aryl or arylhydrocarbyl or on a tertiary nitrogen atom (i.e.
- Examples of such heterocyclyl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl , and the like.
- heteroaryl portion of a heteroaroyl, heteroaryloxycarbonyl , or a heteroarylhydrocarbyloyl (heteroarylhydrocarbyl carbonyl) group or the like is an aromatic monocyclic, bicyclic, or tricyclic heterocycle that contains the hetero atoms and is optionally substituted as defined above with respect to the definition of heterocyclyl.
- a "heteroaryl” group is an aromatic heterocyclic ring substituent that preferably contains one, or two, up to three or four, atoms in the ring other than carbon. Those heteroatoms can be nitrogen, sulfur or oxygen.
- a heteroaryl group can contain a single 5- or 6- membered ring or a fused ring system having two 6- membered rings or a 5- and a 6-membered ring.
- Exemplary heteroaryl groups include 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidihyl , and pyridazinyl; 5-membered ring substituents such as 1,3,5-, 1,2,4- or 1, 2 , 3-triazinyl , imidazyl, furanyl , thiophenyl , pyrazolyl , oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4- oxadiazolyl and isothiazolyl groups; 6-/5-membered fused ring substituents such as benzothiofuranyl , isobenzothiofuranyl , benzisox
- cyclohydrocarbylhydrocarbyloxy- carbonyl means an acyl group derived from a cyclohydrocarbylhydrocarbyloxycarboxylic acid of the formula cyclohydrocarbylhydrocarbyl -0-COOH wherein cyclohydrocarbylhydrocarbylhas the significance given above.
- aryloxyhydrocarbyloyl means an acyl radical of the formula aryl-O-hydrocarbyloyl wherein aryl and hydrocarbyloyl have the significance given above.
- heterocyclyloxycarbonyl means an acyl group derived from heterocyclyl -0-COOH wherein heterocyclyl is as defined above.
- heterocyclylhydrocarbyloyl is an acyl radical derived from a heterocyclyl -substituted hydrocarbylcarboxylic acid wherein heterocyclyl has the significance given above.
- heterocyclylhydrocarbyloxycarbonyl means an acyl radical derived from a heterocyclyl-substituted hydrocarbyl -O-COOH wherein heterocyclyl has the significance given above.
- heteroaryloxycarbonyl means an acyl radical derived from a carboxylic acid represented by heteroaryl -O- COOH wherein heteroaryl has the significance given above .
- aminocarbonyl alone or in combination, means an amino-substituted carbonyl
- (carbamoyl) group derived from an amino-substituted carboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from hydrogen, hydrocarbyl, aryl, aralkyl, cyclohydrocarbyl, cyclohydrocarbylhydrocarbyl radicals and the like.
- aminohydrocarbyloyl means an acyl group derived from an amino-substituted hydrocarbyl- carboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents independently selected from hydrogen, alkyl, aryl, aralkyl, cyclohydrocarbyl, cyclohydrocarbylhydrocarbyl radicals and the like.
- halogen means fluorine, chlorine, bromine or iodine.
- halohydrocarbyl means a hydrocarbyl radical having the significance as defined above wherein one or more hydrogens are replaced with a halogen.
- halohydrocarbyl radicals include chloromethyl , 1-bromoethyl , fluoromethyl , difluoromethyl , trifluoromethyl , 1 , 1 , 1-trifluoroethyl and the like.
- perfluorohydrocarbyl means a hydrocarbyl group wherein each hydrogen has been replaced by a fluorine atom.
- perfluorohydrocarbyl groups in addition to trifluoromethyl above, are perfluorobutyl , perfluoroisopropyl , perfluorododecyl and perfluorodecyl .
- Table 1 through Table 88 show several contemplated sulfonyl aryl or heteroaryl hydroxamic acid compounds as structural formulas that illustrate substituent groups.
- Each group of compounds of Tables 1 through 70 is illustrated by a generic formula, followed by a series of preferred moieties or groups that constitute various substituents that can be attached at the position clearly shown in the generic structure .
- the substituent symbols, e.g., R 1 , R 2 , x are as shown in each Table, and are often different from those shown elsewhere herein in structural formulas bearing Roman numerals of capital letters.
- One or two bonds (straight lines) are shown with those substituents to indicate the respective positions of attachment in the illustrated compound. This system is well known in the chemical communication arts and is widely used in scientific papers and presentations.
- Tables 71 through 88 illustrate specific compounds of the previous tables as well as other contemplated compounds using complete molecular formulas.
- Example -NR'R 0 Example -NR'R 8
- a process (method) for treating a host mammal having a condition associated with pathological matrix metalloprotease activity comprises administering a compound described hereinbefore in an MMP enzyme- inhibiting effective amount to a mammalian host having such a condition.
- the use of administration repeated a plurality of times is particularly contemplated.
- a contemplated compound is used for treating a host mammal such as a mouse, rat, rabbit, dog, horse, primate such as a monkey, chimpanzee or human that has a condition associated with pathological matrix metalloprotease activity.
- contemplated is the similar use of a contemplated compound in the treatment of a disease state that can be affected by the activity of metalloproteases such as TNF- ⁇ convertase.
- exemplary of such disease states are the acute phase responses of shock and sepsis, coagulation responses, hemorrhage and cardiovascular effects, fever and inflammation, anorexia and cachexia.
- a contemplated MMP inhibitor compound in treating a disease condition associated with pathological matrix metalloproteinase activity, can be used, where appropriate, in the form of an amine salt derived from an inorganic or organic acid.
- exemplary acid salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate , dodecylsulfate , ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2 -hydroxy- ethanesulfonate, lactate, maleate, methanesulfonate, nico
- a basic nitrogen-containing group can be quaternized with such agents as lower alkyl (C]_-
- Cg) halides such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibuytl, and diamyl sulfates, long chain (Cg-C2 ⁇ ) halides such as decyl , lauryl, myristyl and dodecyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others to provide enhanced water-solubility . Water or oil-soluble or dispersible products are thereby obtained as desired.
- the salts are formed by combining the basic compounds with the desired acid.
- salts can also form salts. Examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases or basic quaternary ammonium salts .
- the salts can also be used as an aid in the isolation, purification or resolution of the compounds of this invention.
- Total daily dose administered to a host mammal in single or divided doses of an MMP enzyme- inhibiting effective amount can be in amounts, for example, of about 0.001 to about 100 mg/kg body weight daily, preferably about 0.001 to about 30 mg/kg body weight daily and more usually about 0.01 to about 10 mg .
- Dosage unit compositions can contain such amounts or submultiples thereof to make up the daily dose.
- a suitable dose can be administered, in multiple sub-doses per day. Multiple doses per day can also increase the total daily dose, should such dosing be desired by the person prescribing the drug.
- the dosage regimen for treating a disease condition with a compound and/or composition of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as Part of a drug combination.
- the dosage regimen actually employed can vary widely and therefore can deviate from the preferred dosage regimen set forth above .
- a compound useful in the present invention can be formulated as a pharmaceutical composition.
- compositions can then be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired.
- Topical administration can also involve the use of transdermal administration such as transdermal patches or iontophoresis devices.
- parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
- parenteral includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
- Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences. Mack Publishing Co., Easton, Pennsylvania; 1975 and Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms. Marcel Decker, New York, N.Y., 1980.
- sterile injectable preparations for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1 , 3-butanediol .
- acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are sold at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
- a suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are sold at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
- Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules.
- the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os . the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
- Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
- the dosage forms can also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.
- formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.
- solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.
- the compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
- Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
- Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
- Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
- the amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the mammalian host treated and the particular mode of administration.
- Aryl and heteroaryl aryl compounds of this invention as define above by W can be prepared in a similar manner as is known to those skilled in the art. It should be understood that the discussion below refers to both aromatic systems, i. e., heteroaromatics and carbon aromatics, even though only one may be specifically mentioned. In general, the choices of starting material and reaction conditions can vary as is well know to those skilled in the art. Usually, no single set of conditions is limiting because variations can be applied as required and selected by one skilled in the art. Conditions will also will be selected as desired to suit a specific purpose such as small scale preparations or large scale preparations. In either case, the use of less safe or less environmentally sound materials or reagents will usually be minimized.
- An aromatic compound of this invention where y is 1 can be prepared as illustrated by converting a carbonyl group bonded to an aromatic (e .g. , benzene) ring ortho-substituted with a sulfide.
- the sulfide can be prepared via a nucleophilic displacement reaction of the ortho fluoride.
- the nucleophile can be a thiol or thiolate anion prepared from a aryl thiol discussed below.
- a preferred thiol is 4-phenoxybenzenethiol converted in situ into its anion (thiolate) using potassium carbonate in iso-propyl alcohol at reflux temperature .
- the carbonyl group can be a aldehyde, ketone or carboxylic acid derivative, i.e, a protected carboxylic acid or hydroxamate.
- a preferred carbonyl group is an aldehyde and a preferred aldehyde is 2-flourobenzaldehyde (ortho- fluorobenzaldehyde) .
- a ketone can be converted by oxidation into an acid and/or an acid derivative using reagents such as those discussed below for oxidation of a sulfide or other methods well known in the art. It is noted that this oxidation can accomplish the oxidation of a sulfide intermediate into the corresponding sulfone in the same reaction system; i.e., in the same pot, if desired.
- the carbonyl group can then be homologated if desired by reaction with an anion to form an addition compound.
- An example of a homologation reagent is a tri-substituted methane compound such as tetraethyl dimethylammoniummethylenediphosphonate or trimethylorthoformate . Tetraethyl dimethylammonium- methylenediphosphonate is preferred.
- Hydrolysis of the reaction product can provide a phenylacetic substituted on the aromatic ring with a sulfide of this invention. Acid hydrolysis is preferred. Acids and bases are discussed below and hydrochloric acid is preferred.
- the sulfide can then be oxidized to form a sulfone in one or two steps as discused below.
- a preferred oxidizing agent is hydrogen peroxide in acetic acid.
- the carboxylic acid product or intermediate of this invention can then be converted into a protected derivative such as an ester or converted into an activated carboxyl group for reaction with hydroxylamine or and protected hydroxylamine; i.e, a hydroxamate.
- a protected derivative such as an ester
- an activated carboxyl group for reaction with hydroxylamine or and protected hydroxylamine
- hydroxamate i.e, a hydroxamate.
- the conversion of an acid into a hydroxamate is discussed below as is the coupling process and removal of a protecting group if required.
- the preferred protected hydroxamic acid derivative is the O-tetrahydropyranyl compound and the preferred coupling procedure utilizes a diimide (EDC) , hydroxybenzotriazol and DMF solvent for the coupling reaction to form the intermediate hydroxybenzotriazol activated ester.
- EDC diimide
- a preferred reagent for removal of the THP protecting group is hydrochloric acid.
- Alkylation of the acid at the carbon alpha to the carbonyl group to form the compounds of this invention can be carried out by first forming an anion using a base.
- Bases are discussed below.
- the preferred bases are strong bases that are either hindered and/or non-nucleophilic such as lithium amides, metal hydrides or lithium alkyls.
- an alkylating agent an electrophile
- an alkylating agent an electrophile
- Non- limiting examples of such alkylating agents are haloalkanes, dihaloalkanes, haloalkanes also substituted by an activated ester group or activated esters and alkanes substitued with sulfate esters.
- Activated ester groups are well known in the art and can include, for example, an activated ester of an alcohol or a halo compound, an ester of a haloalcohol such as a bromo—, iodo— or chloro- derivative of a tosylate, triflate or mesylate activated ester.
- R 2 and R3 are taken together as defined above, can be prepared using disubstituted alkylating agent; i.e., alkylating agents with two leaving groups in the same molecule.
- alkylating agents i.e., alkylating agents with two leaving groups in the same molecule.
- 1 5-dihalo-diethylether or analogous reagents containing one or more sulfate ester leaving groups replacing one or more halogens can be used to form a pyran ring.
- a similar sulfur, nitrogen or protected nitrogen alkylating agent can be used to form a thiapyran or piperidine ring.
- a thiapyran can be oxidized to form a sulfoxide or a sulfone using methods discussed herein.
- a leaving group in an electrophilic reagent can be a halogen such as chlorine, bromine or iodine or an active ester such as a sulfonate ester, e.g., toluenesulfonate (tosylate), triflate, mesylate and the like as discussed above.
- a cyclic amino acid, heterocycle or alpha-amino acid defined by R 2 and R3 that can include an amino acid (nitrogen heterocycle) , which can be protected or unprotected, into a compound of this invention can be accomplished by alkylation or acylation.
- the carboxylic acid group can be protected with a group such as an alkyl ester such as methyl, ethyl, tert-butyl and the like or a tetrahydropyranyl ester or an arylalkyl ester such as benzyl or it can remain as a carboxylic acid.
- a protected amino acid such as an ethyl ester is preferred.
- the substituent on the heterocycle group is as defined above and can include hydrogen, tert- butoxycarbonyl (BOC or tBOC) , benzyloxycarbonyl (Z) and iso-butyloxycarbonyl groups.
- the amine can be considered as being a protected intermediate as well as being a product of this invention when the N-substituent is not hydrogen.
- the nitrogen substituent on the amino acid portion of the compounds of this invention can be varied. In addition, that variation can be accomplished at different stages in the synthetic sequence based on the needs and objectives of the skilled person preparing the compounds of this invention.
- the nitrogen side chain variations can include replacing the hydrogen substituent with a alkyl, arylalkyl, alkene or alkyne .
- alkylation of the amine with an electrophile such as halo- or sulfate ester (activated ester) derivative of the desired sidechain.
- An alkylation reaction is typically carried out in the presence of a base such as those discussed above and in a pure or mixed solvent as discussed above.
- a preferred base is postassium carbonate and a preferred solvent is DMF .
- the alkenes, arylalkenes, arylalkynes and alkynes so formed can be reduced, for example, by hydrogenation with a metal catalyst and hydrogen, to an alkyl or arylalkyl compound of this invention and a alkyne or arylalkyne can be reduced to a alkene, arylalkene, arylakane or alkane with under catalytic hydrogenation conditions as discussed herein or with an deactivated metal catalyst.
- Catalysts can include, for example, Pd, Pd on Carbon, Pt , Pt ⁇ 2 and the like. Less robust catalysts (deactivated) include such thing as Pd on BaC03 or Pd with quinoline or/and sulfur.
- An alternative method for alkylation of the amine nitrogen is reductive alkylation.
- This process allows treatment of the secondary amine with an aldehyde or ketone in the presence of a reducing agent such as borane, borane:THF, borane :pyridine, lithium aluminum hydride.
- a reducing agent such as borane, borane:THF, borane :pyridine, lithium aluminum hydride.
- reductive alkylation can be carried out under hydrogenation conditions in the presence of a metal catalyst. Catalysts, hydrogen pressures and temperatures are discussed and are well known in the art.
- a preferred reductive alkylation catalyst is borane :pyridine complex.
- an intermediate is a carboxylic acid
- standard coupling reactions well known in the art can be used to form the compounds of this invention including protected intermediates.
- the acid can be converted into an acid chloride, mixed anhydride or activated ester and reacted with an alcohol, amine, hydroxylamine or a protected hydroxylamine in the presence of base to form the amide, ester, hydroxamic acid, protected hydroxamic acid.
- Bases are discussed above and include N-methyl -morpholine, triethylamine and the like.
- Coupling reactions of this nature are well known in the art and especially the art related to peptide and amino acid chemistry. Removal of the protecting group can be accomplished, if desired, using standard hydrolysis conditions such as base hydrolysis or exchange or acid exchange or hydrolysis as discussed.
- the Schemes and/or dicussion also illustrate conversion of a carboxylic acid protected as an ester or amide into an hydroxamic acid derivative such as a O-arylalkylether or O- cycloalkoxyalkylether group such as the THP group.
- hydroxamic acid derivative such as a O-arylalkylether or O- cycloalkoxyalkylether group such as the THP group.
- Methods of treating an acid or acid derivative with hydroxylamine or a hydroxylamine derivative to form a hydroxamic acid or hydroxamate derivative are discussed above.
- Hydroxylamine can be used in an exchange reaction by treatment of a precursor compound where the carboxyl is protected as an ester or amide with one or more equivalents of hydroxylamine hydrochloride or hydroxylamine at room temperature or above to provide a hydroxamic acid directly.
- the solvent or solvents usually protic or protic solvent mixtures such as those listed herein. This exchange process can be further cata
- a base such as a salt of an alcohol used as a solvent, for example, sodium methoxide in methanol
- a base such as a salt of an alcohol used as a solvent, for example, sodium methoxide in methanol
- exchange can be carried out with a protected hydroxyl amine such as tetrahydropyranyl-hydroxyamine (THPONH2) , benzylhydroxylamine (BnONH2) , O— (trimethylsilyl) hydroxylamine and the like, in which case the compounds formed are tetrahydropyranyl
- THPONH2 tetrahydropyranyl-hydroxyamine
- BnONH2 benzylhydroxylamine
- O— (trimethylsilyl) hydroxylamine and the like in which case the compounds formed are tetrahydropyranyl
- THP benzyl
- Bn benzyl
- TMS hydroxamic acid derivatives THP hydroxamic acid derivatives.
- Removal of the protecting groups when desired, for example, following further transformations in another Part of the molecule or following storage, can be accomplished by standard methods well known in the art such as acid hydrolysis of the THP group as discussed above or reductive removal of the benzyl group with hydrogen and a metal catalyst such as palladium, platinum, palladium on carbon or nickel .
- alpha-Amino acids or alpha-hydroxy carboxylic acids or protected carboxylic acids, hydroxamates or hydroxamic acid derivatives or intermediates (precursors) of this invention can be prepared by displacing, for example, a halogen, sulfate ester or other electrophile, from the alpha carbon of an acid or a derivative as listed.
- Methods for the halogenation of acids, esters, acid chlorides and like are well known in the art and include, for example, the HVZ reaction, treatment with O-1CI2, N- bromo— or N-chloro-succinimide, 12 carbon tetraiodide or bromide and the like.
- the halogen can be displaced with a nucleophile in an SN2 reaction. Nucleophiles can include hydroxide, ammonia or amines .
- the aryl or heteroaryl carboxylic acids of this invention where Y is 0 and z is 1 can be prepared from heteroaryl or aryl fused lactones.
- An example of a fused lactone is phthalide.
- a preferred starting material is phthalide.
- This compound can be treated with an thiol, thiolate or metal —SH in order to undergo a SN2 displacement at the methylene carbon to provide a sulfide or thiol compound of this invention or intermediate to a compound of this invention.
- a preferred thiol is 4-phenoxybenzenethiol that is used in the presence of potassium carbonate as a preferred base.
- the sulfide can be oxidized, before or after conversion of the acid to a hydroxamate or hydroxamic acid, to a sulfone of this invention.
- a preferred oxidizing agent is meta-chloroperbenzoic acid.
- a preferred acid activating group is the chloride prepared by reaction of an acid with oxalyl chloride as a preferred reagent.
- a phthalide or a heteroaryl analog of a phthalide can be treated with a Lewis acid such as zinc chloride or zinc bromide along with a halogenating reagent such as phosphorus trichloride or thionyl bromide or the like to form a ortho— (haloalkyl) -aryl acid or ortho— (haloalkyl) — heteroaryl acid derivative. Examples include bromomethyl acid bromides and chloromethyl acid chlorides. These carboxylic acids can be derivatized with protecting groups, hydroxamic acids or hydroxamic acid precursors (hydroxamates) or hydrolyzed to the acid as required.
- a preferred hydroxamate forming reagent is O—
- TMS-hydroxylamine trimethylsilyl hydroxylamine
- removal of the TMS protecting group is preferably accomplished by acid hydrolysis using hydrochloric acid.
- Displacement (SN2) of the halogen in this example by a thiol in the presence of base or a preformed thiolate can be accomplished as discussed and/or shown and as is well known in the art.
- oxidation of the sulfide can be carried out before or after derivatization of the carboxylic acid as discussed to prepare the hydroxamic acids of this invention. Removal of the protecting groups can be carried out using acid hydrolysis or reduction as discussed elsewhere in this document.
- the alcohols of this invention can be protected or deprotected as required or desired.
- Protecting groups can include THP ethers, acylated compounds and various silyl derivatives. These groups, including there protection and removal, are well known in the art.
- bases examples include, for example, metal hydroxides such as sodium, potassium, lithium or magnesium hydroxide, oxides such as those of sodium, potassium, lithium, calcium or magnesium, metal carbonates such as those of sodium, potassium, lithium, calcium or magnesium, metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, primary (1°), secondary (11°) or tertiary (111°) organic amines such as alkyl amines, arylalkyl amines, alkylarylalkyl amines, heterocyclic amines or heteroaryl amines, ammonium hydroxides or quaternary ammonium hydroxides.
- metal hydroxides such as sodium, potassium, lithium or magnesium hydroxide
- oxides such as those of sodium, potassium, lithium, calcium or magnesium
- metal carbonates such as those of sodium, potassium, lithium, calcium or magnesium
- metal bicarbonates such as sodium bicarbonate or potassium bicarbonate
- primary (1°), secondary (11°) or tertiary (111°) organic amines such
- such amines can include triethyl amine, trimethyl amine, diisopropyl amine, methyldiisopropyl amine, diazabicyclononane, tribenzyl amine, dimethylbenzyl amine, morpholine, N- methylmorpholine, N,N' -dimethylpiperazine, N- ethylpiperidine , 1,1,5,5-tetramethylpiperidine, dimethylaminopyridine, pyridine, quinoline, tetramethylethylenediamine and the like.
- Non-limiting examples of ammonium hydroxides can include ammonium hydroxide, triethyl ammonium hydroxide, trimethyl ammonium hydroxide, methyldiiospropyl ammonium hydroxide, tribenzyl ammonium hydroxide, dimethylbenzyl ammonium hydroxide, morpholinium hydroxide, N- methylmorpholinium hydroxide, N,N'- dimethylpiperazinium hydroxide, N-ethylpiperidinium hydroxide, and the like.
- quaternary ammonium hydroxides can include tetraethyl ammonium hydroxide, tetramethyl ammonium hydroxide, dimethyldiiospropyl ammonium hydroxide, benzymethyldiisopropyl ammonium hydroxide, methyldiazabicyclononyl ammonium hydroxide, methyltribenzyl ammonium hydroxide, N,N- dimethylmorpholinium hydroxide, N,N,N', N',- tetramethylpiperazenium hydroxide, and N-ethyl-N'- hexylpiperidinium hydroxide and the like.
- Metal hydrides, amide or alcoholates such as calcium hydride, sodium hydride, potassium hydride, lithium hydride, sodium methoxide, potassium tert-butoxide, calcium ethoxide, magnesium ethoxide, sodium amide, potassium diisopropyl amide and the like can also be suitable reagents.
- Organometallic deprotonating agents such as alkyl or aryl lithium reagents such as methyl, phenyl, butyl, iso-butyl, sec-butyl or tert- butyl lithium, nodium or potassium salts of dimethylsulfoxide, Grignard reagents such as methylmagnesium bromide or methymagnesium chloride, organocadium reagents such as dimethylcadium and the like can also serve as bases for causing salt formation or catalyzing the reaction. Quaternary ammonium hydroxides or mixed salts are also useful for aiding phase transfer couplings or serving as phase transfer reagents.
- Preferred base for use in the alkylation reaction is lithium diisopropyl amide as mentioned above.
- Reaction media in general can be comprised of a single solvent, mixed solvents of the same or different classes or serve as a reagent in a single or mixed solvent system.
- the solvents can be protic, non-protic or dipolar aprotic.
- protic solvents include water, methanol (MeOH) , denatured or pure 95% or absolute ethanol, isopropanol and the like.
- Typical non-protic solvents include acetone, tetrahydrofurane (THF), dioxane, diethylether, tert-butylmethyl ether (TBME) , aromatics such as xylene, toluene, or benzene, ethyl acetate, methyl acetate, butyl acetate, trichloroethane, methylene chloride, ethylenedichloride (EDC), hexane, heptane, isooctane, cyclohexane and the like.
- THF tetrahydrofurane
- TBME tert-butylmethyl ether
- aromatics such as xylene, toluene, or benzene, ethyl acetate, methyl acetate, butyl acetate, trichloroethane, methylene chloride, ethylenedichloride (EDC), hex
- Dipolar aprotic solvents include compounds such as dimethylformamide (DMF) , dimethylacetamide (DMAc), acetonitrile, nitromethane, tetramethylurea, N-methylpyrrolidone and the like.
- Non-limiting examples of reagents that can be used as solvents or as Part of a mixed solvent system include organic or inorganic mono- or multi - protic acids or bases such as hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, formic acid, citric acid, succinic acid, triethylamine, morpholine, N-methylmorpholine, piperidine, pyrazine, piperazine, pyridine, potassium hydroxide, sodium hydroxide, alcohols or amines for making esters or amides or thiols for making the products of this invention and the like.
- Room temperature or less or moderate warming are the preferred temperatures of the reaction. If desired, the reaction temperature might be about -78°C to the reflux point of the reaction solvent or solvents.
- the preferred solvent for an alkylation reaction is tetrahydrofurane (THF) .
- Acids are used in many reactions during various synthesis.
- the Schemes as well as this discussion preparative methods illustrate acid use for the removal of the THP protecting group to produce a hydroxamic acid, removal of a tert-butoxy carbonyl group, hydroxylamine/ester exchange and the like.
- Acid hydrolysis of carboxylic acid protecting groups or derivatives is well known in the art. These methods, as is well known in the art, can use acid or acidic catalysts.
- the acid can be mono-, di- or tri-protic organic or inorganic acids.
- acids include hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, formic acid, citric acid, succinic acid, hydrobromic acid, hydrofluoric acid, carbonic acid, phosphorus acid, p-toluene sulfonic acid, trifluoromethane sulfonic acid, trifluoroacetic acid, difluoroacetic acid, benzoic acid, methane sulfonic acid, benzene sulfonic acid, 2,6- dimethylbenzene sulfonic acid, trichloroacetic acid, nitrobenzoic acid, dinitrobenzoic acid, trinitrobenzoic acid, and the like.
- Lewis acids such as aluminum chloride, borontrifluoride, antimony pentafluoride and the like.
- Contemplated compounds can include compounds wherein a nitrogen of an amine is acylated to provide, for example, amino acid carbamates.
- Non- limiting examples of these carbamates are the carbobenzoxycarbonyl (Z, CBZ, benzyloxycarbonyl) , iso-butoxycarbonyl and tert-butoxycarbonyl (BOC, t- BOC) compounds.
- the materials can be made, as discussed above, at various stages in the synthesis based on the needs and decisions made by a person skilled in the art using methods well know in the art.
- Useful synthetic techniques and reagents include those used in protein, peptide and amino acid synthesis, coupling and transformation chemistry.
- the use of the tert-butoxycarbonyl (BOC) and benzyloxycarbonyl (Z) as will as their synthesis and removal are examples of such protection or synthesis schemes. Transformations of amino acids, amino esters, amino acid hydroxamates, amino acid hydroxamate derivatives and amino acid amides of this invention or compounds used in this invention is discussed herein or/and shown in the schemes. This includes, for example, active ester or mixed anhydride couplings wherein preferred bases, if required, are tertiary amines such as N- methylmorpholine.
- Reagents for protection of the amine group of the protected amino acids include carbobenzoxy chloride, iso-butylchloroformate, tert- butoxycarbonyl chloride, di-tert-butyl dicarbonate and the like which are reacted with the amine in non- protic or dipolar aprotic solvents such as DMF or THF or mixtures of solvents.
- Removal of protecting groups such as carbamates, silyl groups and benzyl, p-methoxybenzyl , or other substituted benzyl groups or diphenylmethyl (benzhydryl) or triphenylmethyl (trityl) can be carried out at different stages in the synthesis of the compounds of this invention as required by methods selected by one skilled in the art. These methods are well known in the art including the amino acid, amino acid coupling, peptide synthesis, peptide mimetic synthesis art. Removal methods can include catalytic hydrogenation, base hydrolysis, carbonyl addition reactions, acid hydrolysis and the like.
- Sulfone compounds such as those where R-*- is nitrobenzene can be prepared as compounds of this invention by synthesis of a thiol, displacement of an electrophile by the nucleophilic thiol or thiolate and oxidation of the product thiol ether to the sulfone.
- displacement of the electrophilic group with a nitro-benzene thiol can yield a compound where R- * - is nitrobenzene, whose nitro group can be reduced to provide a useful amino compound wherein R 1 is an aniline.
- nitrobenzenethiol is an example and not to be considered as limiting or required. Oxidation of the thioether product can be carried out as discussed below when desired.
- nitro groups to amines is well known in the art with a preferred method, being hydrogenation.
- a metal catalyst such as Rh, Pd, Pt , Ni or the like with or without an additional support such as carbon, barium carbonate and the like.
- Solvents can be protic or non-protic pure solvents or mixed solvents as required.
- the reductions can be carried out at atmospheric pressure to a pressure of multiple atmospheres with atmospheric pressure to about 40 pounds per square inch (psi) preferred.
- the resulting amino group can be alkylated if desired. It can also be acylated with, for example, an aroyl chloride, heteroaryl chloride or other amine carbonyl forming agent to form an R-*- amide of this innvention.
- the amino sulfone or thioether can also be reacted with a carbonic acid ester chloride, a sulfonyl chloride, a carbamoyl chloride or an isocyanate to produce the corresponding carbamate, sulfonamides, or ureas of this invention. Acylation of amines of this type are well known in the art and the reagents are also well known .
- thiol reagents can also be used in the preparation of compounds of this invention. Examples are fluoroaryl, fluoroheteroaryl , azidoaryl or azidoheteroaryl or heteroaryl thiol reagents.
- thiols can be used a nucleophiles to as discussed above. Oxidation to the corresponding sulfone can then be carried out.
- the fluoro substituted sulfone can be treated with a nucleophile such as ammonia, a primary amine, a quaternary ammonium or metal azide salt or a hydrazine under pressure if desired, to provide an azido, amino, substituted amino or hydrazino group.
- Azides can be reduced to an amino group using, for example, hydrogen with a metal catalyst or metal chelate catalyst or by an activated hydride transfer reagent .
- the amines can be acylated as discussed above.
- Methods of preparing useful aminethiol intermediates include protection of an aromatic or heteroaromatic thiol with trityl chloride to form the trityl thiol derivative, treatment of the amine with as reagent such as an aromatic or heteraromatic acid chloride to form the amide, removal of the trityl group, with acid to form the thiol.
- Acylating agents include benzoyl chloride and trityl removing reagents include triflouroacetic acid and trisiopropylsilane .
- the fluorine on the fluorosulfones of this invention can also be displaced with other aryl or heteroaryl nucleophiles for form compounds of this invention.
- nucleophiles examples include salts of phenols, thiophenols, —OH group containing aromatic heterocyclic compounds or —SH containing heteroaryl compounds. Tautomers of such groups azo, hydrazo, —OH or —SH are specifically included as useful isomers.
- a preferred method of preparing intermediates in the synthesis of the substituted sulfones is by oxidation of an appropriate acetophenone, prepared from a flouroacetophenone, with for example, peroxymonosulfate, to form the corresponding phenol -ether .
- the phenol -ether is converted into its dimethylthiocarbamoyl derivative using dimethylthiocarbamoyl chloride, rearranged into the dimethylthiocarbamoyl derivative with heat to provide the thiol required for preparation of the thioether intermediate discussed and/or shown in the schemes .
- the compounds of this invention including protected compounds or intermediates can be oxidized to the sulfones as shown in the schemes and/or discussed above.
- the selection of the stage of the alternative synthesis to implement this conversion of sulfides into the sulfones or sulfoxides can be carried out by one skilled in the art.
- Reagents for this oxidation process may, in a non-limiting example, include peroxymonosulfate
- ® (OXONE ) , hydrogen peroxide, meta-chloroperbenzoic acid, perbenzoic acid, peracetic acid, perlactic acid, tert-butyl peroxide, tert-butyl hydroperoxide, tert-butyl hypochlorite, sodium hypochlorite, hypochlorus acid, sodium meta-peroiodate, periodic acid, ozone and the like.
- Protic, non-protic, dipolar aprotic solvents either pure or mixed, can be chosen, for example, methanol/water .
- the oxidation can be carried out at temperature of about -78° to about 50° degrees centigrade and normally selected from a range -10°C to about 40°C.
- Preparation of the sulfones can also be carried out in two steps by the oxidation of a sulfide to a sulfoxide followed by oxidation of the sulfoxide to the sulfone. This can occur in one pot or by isolation of the sulfoxide. This latter oxidation can be carried out in a manner similar to the oxidation directly to the sulfone except that about one equivalent of oxidizing agent can be used preferably at a lower temperature such as about zero degrees C.
- Preferred oxidizing agents include peroxymonosulfate and meta-chloroperbenzoic acid.
- a sulfonamide of this invention can be prepared in a similar manner using methods and procedures discussed hereinbefore.
- Aryl, substituted aryl, heteroaryl or substituted heteroaryl dicarboxylic anhydrides, imides (e.g., phthalic anhydrides or imides) , their sulfonyl analogs or mixed carboxylic-sulfonic acid amides, imides (e.g., 1 , 2-benzenethiazole-3 (2H) -one 1 , 1-dioxides) or anhydrides are useful starting material substrates. Reactions utilizing such substrates can be carried out before or after changes in the substitution patterns of the aryl or heteroaryl rings are made.
- the sulfonamides can also be prepared from heterocyclic compounds such as saccharine, saccharine analogs and saccharine homologs .
- alkylation of sodium saccharine followed by ring opening or ring opening followed by alkylation permits coupling toto form a protected hydroxamic acid derivative such as a THP (tetrahydropyranyl) or TMS (trimethylsilyl) derivative.
- Hydrolysis of the protecting group provides the hydroxamic acid.
- the sulfonamide nitrogen can be further alkylated, acylated or otherwise treated to form various compounds of, for example, Formula VI at this stage of prior to coupling and deprotection.
- treatment of a mixed sulfonic/carboxylic anhydride (2-sulfobenzoic acid cyclic anhydride) with an alcohol or the salt of an alcohol or a protected hydroxamic acid provides a ring opened carboxylic acid derivative (ester or anhydride, respectively) as a sulfonic acid or salt.
- the carboxylic acid derivative so prepared is a product of this invention, and can be converted by standard procedures with reagents such as thionyl chloride, phosphorus pentachloride or the like into a sulfonylhalide .
- Reaction of the sulfonylhalide with a primary amine, secondary amine or ammonia with or without added base provides a sulfonamide or sulfonimide of this invention, a sulfonamide that can be alkylated to produce a sulfonamide of this invention or an intermediate to a sulfonamide of this invention.
- These imides or amides of sulfonamides can be alkylated as desired before or after opening to a benzoic acid substituted sulfonamide or phenylacetic acid substituted sulfonamide.
- Aryl or heteraryl 5- or 6-membered ring thiolactones or dithiolactones are also desirable starting materials for the preparation of compounds of this invention.
- Such thiolactones can be opened to form protected carboxylic acid derivatives such as esters, amides or hydroxylamides before or after changes in the substitution patterns of the aryl or heteroaryl rings are made. Oxidation of the thiol function can be achieved prior to or following substitution changes depending upon the needs and wishes of the skilled chemist.
- Sulfur compounds can also be oxidized directly to sulfonyl chloride compounds using oxidizing agents whose mechanism involved putative positive chlorine species. Oxidizing agents and methods are discussed hereinabove. The sulfonic acid derivatives so obtained are then converted into the sulfonamides of this invention as previously discussed.
- Changes in substitution patterns on the rings of the compounds of this invention can be carried out by processes well known in the art.
- Non- limiting examples of such processes include diazonium chemistry, aromatic ring substitution reactions or addition-elimination sequences, metallation reactions and halogen metal exchange reactions.
- a substituted or unsubstituted aryl or heteroaryl sulfonic acid, sulfonic acid derivative or sulfonamide of this invention can be prepared starting with a halo-sulfonic acid or a sulfonic acid substituted in such a manner that the corresponding anion can be reacted with carbon dioxide, a carbonyl compound, isocyanate, a halogenating reagent, alkylating reagent, acylating reagent , a protected hydroxylamine isocyanate or isothiocyanate derivative to form a compound of this invention or an intermediate to a compound of this invention.
- An anion can be formed via, for example, direct metallation or metal -halogen exchange.
- the substituted or unsubstituted aryl or heteroaryl sulfonic acid, sulfonic acid derivative or sulfonamide can be prepared by sulfonation or chlorosulfonation of the substituted or unsubstituted aryl or heteroaryl compound.
- Metallation reactions as well as halogen-metal exchange reactions to form the salts of the corresponding anions or complexed anions can be carried out by direct treatment with a metal such as lithium, sodium, potassium, palladium, platinum or their compleses, and the like or treatment with a strong base such as tert-butyl lithium, sec-butyl lithium, and the like as discussed above. These intermediates are then quenched with a reagent such as is discussed elsewhere.
- the resulting carboxylic acids or carboxylic acid derivatives are converted into the sulfonamides of this invention by methods and processes known in the art and discussed herein.
- Salts of the compounds or intermediates of this invention are prepared in the normal manner wherein acidic compounds are reacted with bases such as those discussed above to produce metal or nitrogen containing cation salts.
- Basic compounds such as amines can be treated with an acid to form an amine salt .
- some compounds of this invention can be synthesized by biochemical processes, including mammalian metabolic processes. For example, methoxy groups can be converted by the liver in situ into alcohols and/or phenols. Where more than one methoxy group is present, either or both groups can be independently metabolized to hydroxy compounds .
- optical isomers can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or nonracemic mixtures thereof .
- the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes well known in the art, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base.
- Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts.
- a different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers.
- Still another available method involves synthesis of covalent diastereoisomeric molecules, e.g., esters, amides, acetals, ketals, and the like, by reacting compounds of Formula I with an optically active acid in an activated form, a optically active diol or an optically active isocyanate.
- the synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomericaly pure compound. In some cases hydrolysis to the parent optically active drug is not necessary prior to dosing the patient since the compound can behave as a prodrug.
- the optically active compounds of Formula I can likewise be obtained by utilizing optically active starting materials.
- optical isomers or potentially optical isomers are specifically intended to be included in this discussion and in this invention.
- examples include cis isomers, trans isomers, E isomers, Z isomers, syn— isomers, anti— isomers, tautomers and the like.
- Aryl, heterocyclo or heteroaryl tautomers, heteroatom isomers and ortho, meta or para substitution isomers are also included as isomers.
- Solvates or solvent addition compounds such as hydrates or alcoholates are also specifically included both as chemicals of this invention and in, for example, formulations or pharmaceutical compositions for drug delivery.
- a substituent is designated as, or can be, a hydrogen
- the exact chemical nature of a substituent which is other than hydrogen at that position e.g., a hydrocarbyl radical or a halogen, hydroxy, amino and the like functional group, is not critical so long as it does not adversely affect the overall activity and/or synthesis procedure.
- a hydrocarbyl radical or a halogen, hydroxy, amino and the like functional group is not critical so long as it does not adversely affect the overall activity and/or synthesis procedure.
- two hydroxyl groups, two amino groups, two thiol groups or a mixture of two hydrogen-heteroatom groups on the same carbon are known not to be stable without protection or as a derivative.
- salts can also form salts.
- examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases or basic quaternary ammonium salts.
- salts can also be used as an aid in the isolation, purification or resolution of the compounds of this invention.
- R 7 and R 8 are as in Formula VI Scheme 5
- R , R , R , R , and R are as discussed for
- Part B To a solution of the sulfide of Part A (3.00 g, 8.92 mmol) in dichloromethane (28 mL) and DMF (1 drop) was added oxalyl chloride (1.08 mL, 12.4 mmol) and the solution was stirred for one hour. After concentration in vacuo, the residue was dissolved into dichloromethane (16 mL) and the solution was cooled to zero degrees Celsius.
- Tetramethylsilyl hydroxylamine (2.55 mL, 20.8 mmol) was added and the solution was stirred for 1.5 hours.
- the solution was diluted with dichloromethane and washed with 1 N HCl, H0 and saturated NaCl and dried over MgS0 4 . Chromatography (on silica, ethyl acetate/hexane/ toluene) provide the hydroxylamine as a clear paste (970 mg, 31%) .
- Part C To a solution of the hydroxylamine of Part B (970 mg, 2.76 mmol) in dichloromethane (25 mL) cooled to zero degrees Celsius was added 3- chloroperbenzoic acid (60%, 2.14 g, 7.45 mmol) and the solution was stirred for 3 hours at ambient temperature. The solution was diluted with ethyl ether and washed with saturated Na 2 S0 3 , saturated NaHC0 3 and saturated NaCl and dried over MgS0 4 . Reverse phase chromatography (on silica, acetonitrile/H 2 0) provided the title compound as a white solid (345 mg, 33%).
- Part A To a solution of 4- (phenoxy) - benzenethiol (6.06 g, 30.0 mmol) and K 2 C0 3 (4.55 g, 33.0 mmol) in isopropanol (30 mL) was added 2- fluorobenzaldehyde (3.2 mL, 30.0 mmol) . The solution was refluxed for 20 hours. The reaction was quenched by the addition of ice-H 2 0 and was extracted with CHC1 3 . The organic layer was dried over MgS0 4 . Filtration through a pad of silica gel provided the sulfide as a yellow solid (7.43 g, 81 %) .
- Part B A solution of NaH (60 % dispersion in mineral oil, washed with hexane, 264 mg, 6.6 mmol) in THF (12 mL) was cooled to zero degrees Celsius and tetraethyl dimethylammoniummethylene diphosphonate (1.99 g, 6.0 mmol) was added. The solution was warmed to ambient temperature and the sulfide of Part A (1.84 g, 6.0 mmol) was added. The solution was stirred for 4 hours at ambient temperature. The solution was extracted with ethyl acetate and washed with H 2 0 and dried over MgS0 4 .
- Part C To a solution of the acid of Part B (918 mg, 3 mmol) in acetic acid (30 mL) was added 30% hydrogen peroxide (1.2 mL, 12 mmol) and the solution was heated to one hundred degrees Celsius for 40 minutes. The solution was lyophilized and chromatography (hexane/ethyl acetate) provided the sulfone as a foam (697 mg, 63 %) .
- Part D To a solution of the sulfone of Part C (695 mg, 1.89 mmol) in acetonitrile (2 mL) was added O-tetrahydropyranyl hydroxylamine (270 mg, 2.3 mmol). After 5 minutes EDC (442 mg, 2.3 mmol) was added and the solution was stirred for 3 hours. The solution was concentrated in vacuo and the residue was partitioned between ethyl acetate and H 2 0. The organic layer was dried over MgS0 4 . Chromatography (on silica gel, ethyl acetate/hexane) provided the THP-ether as a white foam (688 mg, 77 %) .
- Part E To a solution of the THP-ether of Part D (565 mg, 1.2 mmol) in methanol (10 mL) was added p- toluenesulfonic acid (25 mg) and the solution was stirred at ambient temperature for 2 hours. The solution was concentrated in vacuo and chromatography (chloroform/methanol) provided the title compound as a white solid (339 mg, 74 %) .
- Part A To a solution of 2 -chlorosulfonyl - benzoic acid ethyl ester, prepared per Nagasawa, et . al. J. Med. Chem. 1995, 38, 1865-1871, (5.80 g, 23.0 mmol) in acetonitrile (50 mL) was added 4- benzylpiperidine (4.38 mL, 25 mmol), triethylamine (3.78 mL, 27 mmol) and 4-dimethylaminopyridine (50 mg) . The solution was stirred for 4 hours at ambient temperature and concentrated in vacuo . The residue was dissolved into IN HCl and extracted with ethyl acetate. The organic layer was dried over MgS0 4 and filtered through a pad of silica gel to provide the sulfonamide as an oil (7.45 g, 84 %) .
- Part B To a solution of the sulfonamide of Part A (1.08 g, 2.80 mmol) in methanol (50 mL) and H 2 0 (20 mL) was added KOH (2 g) and the solution was stirred for 3 hours at ambient temperature. The solution was concentrated in vacuo and the remaining aqueous solution was acidified with IN HCl. The solution was extracted with chloroform and the organic layer was dried over MgS0 4 and filtered through a pad of silica gel. Concentration in vacuo provided the acid as a white foam (996 mg, quantitative yield) .
- Part C To a solution of the acid of Part B (415 mg, 1.2 mmol) in acetonitrile (2 mL) was added O-tetrahydropyranyl hydroxylamine (200 mg, 1.7 mmol). After the solution was stirred for 5 minutes EDC (325 mg, 1.7 mmol) was added and the solution was stirred for 3 hours at ambient temperature. The solution was concentrated in vacuo and the residue was dissolved into H 2 0 and extracted with ethyl acetate. The organic layer was dried over MgS0 4 . Chromatography (on silica, ethyl acetate/hexane) provided the THP- ether as a white solid (437 mg, 82 %) .
- Part D To a solution of the THP-ether of Part C (437 mg, 0.98 mmol) in methanol (5 mL) was added p- toluenesulfonic acid (40 mg) and the solution was stirred for 1 hour at ambient temperature. The solution was concentrated in vacuo . Chromatography (ethyl acetate, 1% NH 4 OH) provided the title compound as an oil (122 mg, 34 %) .
- Part B To a solution of the sulfide of Part A
- Part C To a solution of the sulfone of Part B (500 mg, 1.42 mmol) in DMF (2.8 mL) was added 0- tetrahydropyranyl hydroxylamine (173 mg, 1.48 mmol), N-hydroxybenzotriazole (211 mg, 1.56 mmol) and EDC (299 mg, 1.56 mmol) and the solution was stirred for 18 hours at ambient temperature.
- Part D To a solution of the ester of Part C (570 mg, 1.26 mmol) in methanol (10 mL) was added p- toluenesulfonic acid (15 mg) and the solution was stirred at ambient temperature for 1.5 hours. The solution was concentrated in vacuo and reverse phase chromatography (acetonitrile/H0) provided the title compound as a white solid (244 mg, 53 %) .
- Part B To a solution of 4- (phenoxy) benzene sulfonyl chloride, prepared per J. Am. Chem. Soc., 1931, 93, 1112-1115) (341 mg, 1.27 mmoL) in pyridine (2 mL) cooled to zero degrees Celsius was added the THP-ether of Part B (300 mg, 1.27 mmol) and the solution was stirred at zero degrees Celsius for 3 hours. The solution was concentrated in vacuo and the residue was dissolved in 1 N HCl and was extracted with ethyl acetate. The organic layer was washed with 1 N HCl, H 2 0 and saturated NaCl and dried over MgS0 . Chromatography (on silica gel, ethyl acetate/hexane) provided the sulfone as a white solid (321 mg, 54%). MS(CI) MH + calculated for C 24 H 24 N 2 0 6 S:
- Part C Into a solution of the sulfone of Part B (320 mg, 0.68 mmol) in methanol (3 mL) cooled to zero degrees Celsius was bubbled HCl gas for 5 minutes. The solution was concentrated in vacuo and the residue was triturated with ethyl ether. Collection by vacuum filtration provided the title compound as a pink solid (163 mg, 62 %) . MS (Cl) MH + calculated for C ⁇ 9 Hi 6 N 2 0 d S : 385, found 385. Analytical calculation for C 19 H 16 N 2 O 6 S*0.2H 2 0: C, 58.81; H, 4.26; N, 7.22; S, 8.26. Found: C, 58.88; H, 4.37; N, 6.98; S, 7.83.
- Part A A 500 mL round bottom flask equipped with magnetic stir bar and N 2 inlet was charged with 1.5 mL (1.7 g, 12.0 mM) 4-methoxybenzenethiol and 2.5 g (10.9 mM) methyl (2-bromomethyl) benzoate in acetone (100 mL) . The solution was treated with 1.8 g (13.1 mM) potassium carbonate and heated at 55°C in an oil bath. The reaction mixture was stirred at 55°C for 17 hours, then concentrated in vacuo.
- Part B A 500 mL round bottom flask equipped with magnetic stir bar and N 2 inlet was charged with 3.1 g (10.8 mM) of product from Part A in 90 mL MeOH. The solution was then treated with 15 mL water and 13.9 g (22.6 mM) Oxone ® . The reaction mixture was stirred 17 hours, then filtered. The filter cake was washed with MeOH, and the filtrate was concentrated in vacuo . The residue was partitioned between EtOAc and H 2 0, the layers were separated and the aqueous layer was extracted with EtOAc (2X) .
- Part D A 2 -necked 50 mL round bottom flask equipped with addition funnel, thermometer, magnetic stir bar and N 2 inlet was charged with 1.0 mL of DMF in 10 mL CHC1 2 . The solution was cooled in an ice bath, then treated with 3.5 mL (0.9 g, 6.9 mM) of a 2.0 M oxalyl chloride solution in CH 2 C1 2 , then with a solution of 1.0 g (3.3 mM) of product from Part C in 5 mL DMF. The bath was removed and the reaction was stirred for 1 hour.
- That reaction mixture was added to a 2 -necked 100 mL round-bottomed flask equipped with addition funnel, thermometer, magnetic stir bar and N 2 inlet and containing a cooled solution of 2.1 mL (1.1 g, 37.7 mM) of 50% aqueous hydroxylamine in THF (25 mL) . The bath was then removed and the reaction mixture was stirred for 2 hours.
- Part A A 3 -necked 100 mL round bottom flask equipped with addition funnel, thermometer, magnetic stir bar and N 2 inlet was charged with 0.5 g (4.3 mM) of p-anisidine and 1.8 mL (1.3 g, 12.8 mM) triethylamine in CH 2 C1 2 (20 mL) . The solution was cooled in an ice bath, then treated with a solution of 1.0 g (4.3 mM) methyl (2 -chlorosulfonyl) benzoate in CH 2 C1 2 (10 mL) . The reaction mixture was stirred for 17 hours, then concentrated in vacuo .
- Part B A 100 mL round bottom flask equipped with magnetic stir bar and N 2 inlet was charged with 0.7 g (2.1 mM) of the product from Part A and 0.7 g (10.2 mM) of hydroxylamine hydrochloride in 10 mL MeOH. The reaction was cooled to zero degrees C and charged with 0.4 g (16.4 mM) of sodium metal. After stirring for 17 hours, the reaction was concentrated in vacuo, the residue was slurried in 20 mL of water, then acidified using 2 N HCl solution. The aqueous slurry was extracted with EtOAc (3X) .
- Part A A 3 -necked 100 mL round bottom flask equipped with addition funnel, thermometer, magnetic stir bar and N 2 inlet was charged with 0.5 mL (0.5 g, 4.3 mM) of benzylamine and 1.8 mL (1.3 g, 12.8 mM) triethylamine in CH 2 C1 2 (20 L) . The solution was cooled in an ice bath, then treated with a solution of 1.0 g (4.3 mM) methyl (2 -chlorosulfonyl) benzoate in CH 2 C1 2 (10 mL) . The reaction mixture was stirred for 2 hours, then concentrated in vacuo .
- Part B A 100 mL round bottom flask equipped with magnetic stir bar and N 2 inlet was charged with 0.7 g (2.1 mM) of the product from Part A and 0.7 g (10.6 mM) of hydroxylamine hydrochloride in 10 mL MeOH. The reaction was cooled to zero degrees C and charged with 0.4 g (17.0 mM) of sodium metal. After stirring for 17 hours, the reaction was concentrated in vacuo, the residue was slurried in 20 mL of water, then acidified using 2 N HCl solution. The aqueous slurry was extracted with EtOAc (3X) .
- Part B The ester sulfonamide from Part A (938 mg, 2.51 mmol) was stirred for 20 hours at ambient temperature in the presence of potassium hydroxide
- Part C To a solution of the acid from Part B (764 mg, 2.2 mmol) dissolved in acetonitrile (15 mL) was added O-tetrahydropyranyl hydroxylamine (351 mg, 3.0 mmol) and N-hydroxybenzotriazole (405 mg, 3.0 mmol), followed by 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (600 mg, 3 mmol) . The reaction was stirred for 16 hours and then concentrated. The residue was diluted with half- saturated brine (15 mL) and extracted with ethyl acetate (100 mL) . The organic phase was dried using magnesium sulfate, concentrated, and the residue was purified by silica gel chromatography affording, on concentration, the desired THP-protected hydroxamate as a white foam (833 mg, 82%) .
- Part D The THP-protected hydroxamate from Part C (833 mg, 1.8 mmol) was dissolved in absolute methanol (3 mL) . Acetyl chloride (0.28 mL, 4 mmol) was added drop-wise. After 3 hours, the reaction was concentrated, and the residue was subjected to purification by chromatography, affording the title compound (430 mg, 66 %) as a white foam.
- Anal. calculated for C 18 H 20 N 2 O 4 S (H 2 0) C, 57.08; H, 5.81;
- Part A 2 -Bromobenzenesulfonyl chloride (2.56 g, 10 mmol) was added to a solution of 4- phenylpiperidine (1.61 g, 10 mmol), triethylamine (2.0 mL, 14 mmol), 4-dimethylaminopyridine (75 mg) , and acetonitrile (20 mL) . After 24 hours, water (100 mL) was added. The mixture was extracted with ethyl acetate (100 ml, then 50 mL) . The combined organic layers were dried over magnesium sulfate, filtered through silica, and concentrated to afford the bromo sulfonamide as a white solid (3.47 g, 96%) .
- Part B The bromo sulfonamide (359 mg, 1 mmol) was dissolved in dry tetrahydrofuran (2 mL) and cooled to minus seventy-eight degrees. t- Butyllithium (0.68 mL, 1.7 M in pentane) was added drop-wise and the anion was permitted to form over 15 minutes. Ethyl pyruvate (0.11 mL, 1.15 mmol) was added. The cooling bath was removed. When the reaction reached ambient temperature, the mixture was quenched with water (10 mL) and extracted with ethyl acetate (100 mL) . The organic layer was dried over magnesium sulfate, filtered through silica, concentrated, and chromatographed to afford the desired hydroxy ester as a glass (163 mg 40 %) .
- Part C The hydroxy ester from Part B (134 mg, 0.33 mmol) was stirred in the presence of potassium hydroxide (134 mg, 2.4 mmol) in ethanol (1 mL) and water (1 mL) . After 4 hours the mixture was heated at 50 degrees Celsius for one hour, then cooled, neutralized with dilute hydrochloric acid, concentrated, and azeotroped to dryness with acetonitrile to afford the crude hydroxy acid, which was used directly as is. The hydroxy acid was diluted with acetonitrile (1 mL) . 0-
- Tetrahydropyranylhydroxylamine (117 mg, 1.0 mmol) and N-hydroxybenzotriazole (135 mg, 1.0 mmol) were added, followed by 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (191 mg, 1 mmol) .
- the reaction was stirred overnight (about 18 hours) , then diluted with water (10 mL) and extracted with ethyl acetate (50 mL) . The organic layer was dried over ethyl acetate, concentrated and chromatographed to afford the THP-protected hydroxamate as a glass (80 mg, 48%) .
- Part D The THP-protected hydroxamate from Part C (80 mg) was diluted with absolute methanol (4 mL) , and toluenesulfonic acid (6 mg) was added. After 3 hours, the reaction mixture was concentrated, and the residue was chromatographed using 1:1 hexane: ethyl acetate 1% NH ⁇ OH. The title compound was isolated as a white foam (40 mg, 60%) . Analysis calculated for C 20 H 24 N 2 O 5 S(1.33 H 2 0) : C, 53.75; H, 5.90; N, 6.27.
- 3 -Aminopyrrolidine (636 mg, 4 mmol) , triethylamine (2.7 mL, 20 mmol), and 4- (dimethylamino) pyridine (75 mg) were suspended in acetonitrile. After 10 minutes, the reaction was chilled to zero degrees Celsius. 4 -Methoxybenzoyl chloride (0.54 mL, 4 mmol) was added, drop-wise. After 30 minutes, 2-carboethoxybenzenesulfonyl chloride (0.996 g, 4.0 mmol) was introduced, drop- wise, by syringe. The mixture was stirred at zero Celsius for 1 hour, then at ambient temperature for 2 hours. Water was added (50 mL) .
- the mixture was extracted using ethyl acetate (2 X 50 mL) .
- the organic layer was dried over magnesium sulfate, filtered through silica, and concentrated.
- the residue was purified using silica gel chromatography using 1:1 ethyl acetate : hexane to ethyl acetate as eluant .
- the desired amide sulfonamide was isolated as a foam (282 mg,16%).
- Part B The amide sulfonamide from Part A (272 mg,0.63 mmol) was combined with potassium hydroxide (156 mg, 2.8 mmol ) , ethanol (3 mL) , and water (2 mL) and was brought to reflux. After 40 minutes, the reaction was permitted to cool. Acetic acid (0.1 mL) and absolute ethanol (20 mL) were added. Concentration followed by chromatography (9:1 ethyl acetate : methanol to methanol; 20 g silica gel) afforded the desired acid as a crystalline solid (229 mg, 96%). The acid (229 mg, 0.57 mmol) was dissolved in acetonitrile (1 mL) .
- Part B A solution of the amine of Part A (1.90 g, 7.28 mmol), ethyl 2-chlorosulfonylbenzoate (1.70, 6.85 mmol), triethylamine (1.15 mL, 8.22 mmol), and 4-dimethylaminopyridine (10 mg) in acetonitrile (20 mL) was stirred under an atmosphere of nitrogen at ambient temperature for 18 hours. After concentrating the solution, the residue was diluted with H 2 0 and extracted into ethyl acetate. The organic layer was washed with 1.0 N KHS0 4 , saturated NaHC0 3 , H 2 0, and brine; and then dried over MgS0 4 and concentrated to a yellow oil.
- Part C A solution of the sulfonamide of Part B (1.45 g, 3.17 mmol) and potassium hydroxide (1.77 g, 31.7 mmol) in a mixture of MeOH (30 mL) , H 2 0 (10 mL) , and THF (10 mL) was heated at reflux for 1.5 hours.
- Part D A solution of the acid of Part C (0.97 g, 2.18 mmol), N-hydroxybenzotriazole (0.89 g, 6.50 mmol), 4 -methylmorpholine (0.71 mL, 6.50 mmol), O- tetrahydro-2H-pyran-2-yl-hydroxylamine (0.51 g, 4.36 mmol) , and 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (1.25 g, 6.50 mmol) in DMF (19 mL) was stirred at ambient temperature under a nitrogen atmosphere for 20 hours. The mixture was concentrated in vacuo, diluted with water, and extracted with ethyl acetate.
- Part E The THP-protected hydroxamate of Part D
- Acetyl chloride (0.36 mL, 5.0 mmol) was added. After 1 hour, the solution was concentrated, and the residue was subjected to chromatography (1:1 hexane: ethyl acetate; 1% NH 4 0H to ethyl acetate; 1%
- Part A A solution of N- (tert-butyloxy- carbonyl) -4-piperidinol (5.00 g, 2.48 mmol), 4- fluorobenzo-trifluoride (3.46 mL, 2.73 mmol), and cesium carbonate (12.1 g, 3.72 mmol) in DMF (60 mL) was heated at 120 degrees Celsius under an atmosphere of nitrogen for 2 days. The mixture was concentrated, diluted with H 2 0, and extracted with ethyl acetate. The organic layer was washed with H 2 0 and brine, dried with MgS0 , and concentrated in vacuo .
- Part B A solution of the BOC-aminoether of Part A (4.00 g, 11.6 mmol) and p-toluenesulfonic acid (6.61 g, 34.7 mmol) in CH 2 C1 2 (30 mL) at ambient temperature under an atmosphere of nitrogen was stirred for 3 hours and then concentrated in vacuo .
- Part C A solution of the amine of Part B (1.57 g, 6.40 mmol), ethyl 2-chlorosulfonylbenzoate (1.57 g, 6.03 mmol), triethylamine (1.00 mL, 7.24 mmol), and 4-dimethylaminopyridine (10 mg) in acetonitrile (20 mL) was stirred under an atmosphere of nitrogen at ambient temperature for around 1.5 hours. After concentrating the solution, the residue was diluted with H 2 0 and extracted into ethyl acetate.
- Part D A solution of the sulfonamide of Part C (2.50 g, 5.46 mmol) and potassium hydroxide (3.06 g, 54.6 mmol) in a mixture of MeOH (49 mL) and H 2 0 (24 mL) was heated at reflux for 4 hours. After the solution was concentrated in vacuo, the residue was triturated with ethyl ether, dissolved into H0, acidified with concentrated HCl, and extracted into ethyl acetate.
- Part E A solution of the acid of Part D (2.10 g, 4.89 mmol), N-hydroxybenzotriazole (1.97 g, 14.6 mmol), 4 -methylmorpholine (1.61 mL, 14.6 mmol), O- tetrahydro-2H-pyran-2-yl -hydroxylamine (1.15 g, 9.79 mmol), and 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (2.80 g, 14.6 mmol) in DMF (43 mL) was stirred at ambient temperature under a nitrogen atmosphere for about 18 hours. The mixture was concentrated in vacuo, diluted with water, and extracted into ethyl acetate.
- Part F To a solution of the THP-protected hydroxamate of Part C (1.80 g, 3.41 mmol) in methanol (24 mL) was added acetyl chloride (0.73 mL, 10.2 mmol) and the solution was stirred at ambient temperature under a nitrogen atmosphere for 1.5 hours. The solution was concentrated in vacuo and chromatography (on silica, MeOH/CHCl 3 ) provided the title compound as an off white solid (1.18 g, 78%) : Anal, calculated, for C ⁇ 9 H ⁇ 9 N 2 O 5 F 3 S-0.2%H 2 0 : C, 50.94; H, 4.36; N, 6.25; S, 7.16. Found: C, 50.88; H, 4.31; N, 6.20; S, 7.43. MS MH+ calculated, for C ⁇ 9 H 19 N 2 0 5 F 3 S : 445, found 445.
- Part A A solution of 4- (trifluoromethyl) benzyl bromide (2.00 mL, 12.9 mmol) in THF (6 mL) was added drop-wise under an atmosphere of nitrogen to a -52 degrees Celsius mixture of N- (tert-butyloxycarbonyl) - 4-piperidinol (2.85, 14.9 mmol) and 60% sodium hydride (0.600 g, 14.9 mmol) in THF (15 mL) and then stirred at ambient temperature for about 20 hours. The reaction mixture was quenched with a saturated NH 4 C1 solution, concentrated in vacuo, diluted with H 2 0, and extracted with ethyl acetate.
- Part B A zero degrees Celsius solution of the BOC-aminoether of Part A (3.35 g, 9.32 mmol) in ethyl acetate (40 mL) was saturated with HCl (gas) and the stirred at ambient temperature for 1 hour. After concentrating in vacuo and triturating with ethyl ether, the crude free base was partitioned between aqueous NaHC0 3 and ethyl ether. The organic layer was washed with H 2 0 and brine, dried over MgS0 4 , and concentrated in vacuo to provide the amine as a clear, yellow oil (2.11 g, 87%), which had a proton NMR spectrum consistent for the desired product .
- Part C A solution of the amine of Part B (2.11 g, 8.14 mmol), ethyl 2 -chlorosulfonylbenzoate (2.65 g, 10.7 mmol), triethylamine (1.75 mL, 12.6 mmol), and 4-dimethylaminopyridine (50 mg) in acetonitrile (25 mL) was stirred under an atmosphere of nitrogen at ambient temperature for about 18 hours. After concentrating the solution, the residue was diluted with 1.0 N KHS0 4 and extracted into ethyl acetate.
- Part D A solution of the sulfonamide of Part C (2.10 g, 4.45 mmol) and potassium hydroxide (2.49 g, 44.5 mmol) in a mixture of MeOH (40 mL) , H 2 0 (20 mL) , and THF (4 mL) was heated at reflux for 1.5 hours. After the solution was concentrated in vacuo, the residue was triturated with ethyl ether, dissolved into H 2 0, acidified with concentrated HCl, and extracted into ethyl acetate .
- Part E A solution of the acid of Part D (2.00 g, 4.51 mmol), N-hydroxybenzotriazole (1.83 g, 13.5 mmol), 4 -methylmorpholine (1.48 mL, 13.5 mmol), O- tetrahydro-2H-pyran-2-yl -hydroxylamine (1.06 g, 9.02 mmol) , and 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (2.59 g, 13.5 mmol) in DMF (40 mL) was stirred at ambient temperature under a nitrogen atmosphere for about 20 hours. The mixture was concentrated in vacuo, diluted with water, and extracted into ethyl acetate.
- Part F To a solution of the THP-protected hydroxamate of Part E (2.00 g, 3.69 mmol) in methanol (25.9 mL) was added acetyl chloride (0.78 mL, 11.1 mmol), and the solution was stirred at ambient temperature under a nitrogen atmosphere for 1.5 hours. The solution was concentrated in vacuo and chromatography (on silica, MeOH/CHCl 3 ) provided the title compound as an off-white solid (1.07 g, 63%) : Anal, calculated, for C 20 H 2 ⁇ N 2 O 5 F 3 S : C, 52.40; H, 4.62; N, 6.11; S, 6.99. Found: C, 52.53; H, 4.74; N, 6.25; S, 7.16. MS MH+ calculated, for C 2 oH 21 N 2 0 5 SF 3 : 459, found 459.
- Part A A solution of 4-phenoxyaniline (3.43 g, 18.5 mmol), ethyl 2 -chlorosulfonylbenzoate (4.25 g, 17.1 mmol), triethylamine (2.81 mL, 20.1 mmol), and 4-dimethylaminopyridine (50 mg) in acetonitrile (40 mL) was stirred under an atmosphere of nitrogen at ambient temperature for about 18 hours. After concentrating the solution, the residue was diluted with 1.0 N KHS0 4 and extracted into ethyl acetate. The organic layer was washed with 1.0 N KHS0 4 , H 2 0, and brine, and then dried over MgS0 4 and concentrated in vacuo .
- Part B A solution of the sulfonamide of Part A (3.00 g, 7.55 mmol) and potassium hydroxide (4.23 g, 75.5 mmol) in a mixture of MeOH (68 mL) , THF (8 mL) , and H 2 0 (33 mL) was heated at reflux for 2 hours. After the solution was concentrated in vacuo, the residue was triturated with ethyl ether, dissolved into H 2 0, acidified with concentrated HCl, and extracted into ethyl acetate. The organic layer was washed with 1.0 N HCl, H 2 0, and brine, dried over
- Part C A solution of the acid of Part B (2.30 g, 6.23 mmol), N-hydroxybenzotriazole (2.52 g, 18.6 mmol), 4 -methylmorpholine (2.04 mL, 18.6 mmol), O- tetrahydro-2H-pyran-2-yl -hydroxylamine (1.46 g, 12.5 mmol), and 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (3.57 g, 18.6 mmol) in DMF (55 mL) was stirred at ambient temperature under a nitrogen atmosphere for about 18 hours. The mixture was diluted with water, and extracted into ethyl acetate.
- Part D A solution of the saccharin of Part C (0.500 g, 1.42 mmol) and 0-tetrahydro-2H-pyran-2-yl- hydroxylamine (0.183 g, 1.56 mmol) in dioxane (2 mL) under an atmosphere of nitrogen was stirred for 6 days at ambient temperature and 1 day at 50 degrees Celsius. The solution was concentrated and chromatography provided the THP-protected hydroxamate as a white solid (0.285 g, 43%); MS MH + calculated for C 24 H 24 N 2 0 6 S: 469, found 469.
- Part E To a solution of the THP-protected hydroxamate of Part D (0.275 g, 0.587 mmol) in methanol (5 mL) was added acetyl chloride (0.150 mL, 2.13 mmol) and the solution was stirred at ambient temperature under a nitrogen atmosphere for 2 hours. The solution was concentrated in vacuo and chromatography (on silica, MeOH/CHCl 3 ) provided the title compound as an off-white solid (1.18 g, 78%) . The proton NMR was consistent for the desired product .
- Part A The piperidine from Example 13, Part B (as the hydrochloride) (1.12 g, 4.0 mmol) was dissolved in a mixture of acetonitrile (6 ml), triethylamine (1.3 mL, 9.0 mmol), and N,N- dimethylaminopyridine (80 mg) . 3,4-
- Part C The acid from Part B (231 mg, 0.47 mmol) was dissolved in methylene chloride (4 mL) . N,N-Dimethylformamide (2 drops) was added, followed by oxalyl chloride (0.35 mL, 4 mmol) . The reaction was stirred for 1.5 hours at ambient temperature, during which time gas was evolved. The reaction mixture was concentrated, and dried in vacuo, affording crude acid chloride, which was used as is. To the acid chloride was added a solution of 0- tetrahydropyranylhydroxylamine (234 mg, 2.0 mmol) and pyridine (0.5 mL, 6.0 mmol) in acetonitrile (2-3 mL) .
- the reaction was stirred at ambient temperature for 16 hours, then was diluted with water (3 mL) .
- the mixture was extracted with ethyl acetate (100 mL, then 50 mL) .
- the combined organic layers were dried over magnesium sulfate, filtered through a silica pad, and concentrated, affording 376 mg of crude THP- protected hydroxamate.
- the THP-protected hydroxamate was used directly without purification and was diluted with absolute methanol (10 mL) .
- Acetyl chloride (0.36 mL, 5.0 mmol) was added, drop-wise.
- Part D A solution of the sulfonamide of Part C (0.85 g, 1.9 mmol) and potassium hydroxide (1.07 g, 19.2 mmol) in a mixture of MeOH (17 mL) and H 2 0 (8 L) was heated at reflux for 4 hours. After the solution was concentrated in vacuo, the residue was dissolved into H 2 0, acidified with concentrated HCl, and extracted into ethyl acetate. The organic layer was washed with H 2 0 and brine, dried over MgS0 4 , and concentrated in vacuo to provide the acid as a clear, colorless wax (0.74 g, 93%); MS MH + calculated for C 18 H 16 N0 5 F 3 S : 415, found 416.
- Part E A solution of the acid of Part D (0.690 g, 1.56 mmol), N-hydroxybenzotriazole (0.629 g, 4.65 mmol), 4 -methylmorpholine (0.51 mL, 4.7 mmol), O- tetrahydro-2H-pyran-2 -yl-hydroxylamine (0.340 g, 2.90 mmol) , and 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (0.891 g, 4.65 mmol) in DMF (13 mL) was stirred at ambient temperature under a nitrogen atmosphere for 3 days.
- Part F To a solution of the THP-protected hydroxamate of Part E (0.500 g, 0.972 mmol) in methanol (6 mL) was added acetyl chloride (0.24 mL, 3.5 mmol) and the solution was stirred at ambient temperature under a nitrogen atmosphere for 4.5 hours. The solution was concentrated in vacuo and chromatography (on silica, MeOH/CHCl 3 ) provided the title compound as a white solid (0.325 g, 77.8%): MS MH+ calculated, for C 18 H ⁇ 7 N 2 0 5 SF 3 : 430, found 431.
- Part A A mixture of 4- [ (4-trifluoromethyl) - phenoxy] piperidine hydrochloride (the hydrochloride from the product of Example 13, Part B (2.50 g, 8.87 mmol), 2 -bromobenenesulfonyl chloride (2.16 g, 8.45 mmol), triethylamine (2.51 mL, 18.0 mmol), and 4- (dimethylamino) pyridine (20 mg) in acetonitrile (25 mL) was stirred at ambient temperature under an atmosphere of nitrogen for 18 hours, concentrated in vacuo, and partitioned between H 2 0 and ethyl acetate.
- Part B To a -78 degree Celsius solution of the sulfonamide from Part A (3.68 g, 7.93 mmol) in anhydrous THF (40 mL) under an atmosphere of nitrogen was added 1.7 M tert-butyl lithium (9.35 mL, 15.9 mmol) . The reaction was maintained at -78 degrees Celsius for 1 hour, warmed up to -30 degrees Celsius, and then cooled down to -78 degrees Celsius. A 50% ethyl glyoxalate solution in toluene was added drop- wise while maintaining the reaction mixture at a temperature below -50 degrees Celsius.
- Part C A solution of the ester of Part B (1.35 g, 2.77 mmol) and potassium hydroxide (1.55 g, 27.7 mmol) in a mixture of MeOH (24.5 mL) and H 2 0 (14.7 mL) was stirred at ambient temperature for 1 hour. The solution was concentrated in vacuo, dissolved into a mixture of H 2 0 and acetonitrile, acidified with concentrated HCl, and extracted with ethyl acetate.
- Part D A solution of the acid of Part C (1.00 g, 2.18 mmol), N-hydroxybenzotriazole (0.876 g, 6.48 mmol), 4 -methylmorpholine (0.712 mL, 6.48 mmol), O- tetrahydro-2H-pyran-2-yl -hydroxylamine (0.474 g, 4.05 mmol), and 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (1.24 g, 6.48 mmol) in DMF (15 mL) was stirred at ambient temperature under a nitrogen atmosphere for 18 hours. The mixture was concentrated in vacuo, diluted with water, and extracted with ethyl acetate.
- Part E A solution of the THP-protected hydroxamate of Part D (0.800 g, 1.43 mmol) and acetyl chloride (0.36 mL, 5.2 mmol) in methanol (15 mL) was stirred at ambient temperature under a nitrogen atmosphere for 1.5 hours. The solution was concentrated in vacuo and purified by preparatory HPLC (CH 3 CN/H 2 0) to provide the title compound as a white solid (0.310 g, 45%). Anal, calculated, for C 20 H 21 N 2 O 6 SF 3 -0.2%H 2 O: C, 50.25; H, 4.51; N, 5.86; S, 6.71.
- Part A A solution of the piperidine from Example 13, Part B (as the hydrochloride) (2.0 g, 6.72 mmol), 3 -flourobenzenesulphonyl chloride (1.19 g, 6.11 mmol), triethylamine (2.13 mL, 15.3 mmol), and 4-dimethylaminopyridine (10 mg) in acetonitrile (10 mL) was stirred under an atmosphere of argon at ambient temperature for 18 hours. After concentrating the solution, the residue was diluted with H 2 0 and extracted into ethyl acetate. The organic layer was washed with saturated NaHS0 4 , H 2 0, and brine; and dried over MgS0 and concentrated to an oil.
- Part C A solution of the acid of Part B (88O mg, 1.97 mmol), N-hydroxybenzotriazole (319 mg, 2.36 mmol), 4 -methylmorpholine (0.649 mL, 5.91 mmol), O- tetrahydro-2H-pyran-2-yl -hydroxylamine (346 mg, 2.95 mmol), and 1- (3-dimethylaminopropyl) -3 - ethylcarbodiimide hydrochloride (528 mg, 2.76 mmol) in DMF (10 mL) was stirred at ambient temperature under an argon atmosphere for 18 hours, followed by stirring at 60°C for 24 hours.
- Part D To a solution of the THP-protected hydroxamate of Part C (230 mg, 0.422 mmol), in dioxane (5 mL) was added 4 N HCl (1 mL) , and the solution was stirred at ambient temperature under argon atmosphere for 1 hour. The solution was concentrated in vacuo to give an oil . Chromatography on a C-18 reverse phase column, eluting with acetonitrile/water afforded the titled hydroxamate as a white foam (180 mg, 92%) .
- Part A A solution of the amine of piperidine from Example 13, Part B (as the hydrochloride) (2.00 g, 6.72 mmol), 3-chlorobenzenesulphonyl chloride (1.29 g, 6.11 mmol), triethylamine (2.2 mL, 15.3 mmol), and 4-dimethylaminopyridine (10 mg) in acetonitrile (10 mL) was stirred under an atmosphere of argon at ambient temperature for 18 hours. After concentrating the solution, the residue was diluted with H 2 0 and extracted into ethyl acetate. The organic layer was washed with saturated NaHS0 4 , H 2 0, and brine, and dried over MgS0 4 and concentrated to an oil.
- Part C Oxalyl chloride (0.154 mL) was added to a solution of the acid of Part B (410 mg, 0.88 mmol) in methylene chloride (4 mL) at ambient temperature and the solution was stirred under argon atmosphere for 1 hour. The solution was concentrated in vacuo to give the acid chloride. To the acid chloride in DMF (5 mL) was added 4 -methylmorpholine (0.200 mL, 1.77 mmol), 0-tetrahydro-2H-pyran-2 -yl -hydroxylamine (155 mg, 1.30 mmol) and the reaction was stirred at ambient temperature under an argon atmosphere for 4 hours. The mixture was diluted with water, and extracted with ethyl acetate.
- Part B A solution of hydrogen chloride in 1,4- dioxane (20 mL of a 4 N solution, 80 mmol) is added to a solution of pyridyloxypiperidine of Part A (3.81 g, 13.7 mmol) in 1,4-dioxane (28 mL) at ambient temperature. After one hour, the suspension is concentrated and the residue triturated with hot iso- propanol . The resulting solid is dried at 50 degrees Celsius under vacuum to afford the desired piperidine hydrochloride salt as a white powder (3.03 g, 88%) . Analytical calculation for Ci 0 H ⁇ 4 N 2 0.2HC1 : C, 47.82; H, 6.42; N, 11.15.
- Part C The solid piperidine hydrochloride from Part B (450 mg, 1.79 mmol) is added to a solution of 2 -carboxyethoxy-benzenesulfonyl chloride (580 mg, 2.33 mmol) in acetonitrile (5 mL) , followed by the addition of neat triethylamine (0.95 mL, 7.16 mmol) and dimethylaminopyridine (10 mg, 0.08 mmol). Additional acetonitrile (10 mL) is added, along with methylene chloride (3 mL) to aid in dissolution.
- Part D Sodium hydroxide (10 equivalents) is added to a solution of the aryl sulfonamide of Part C in ethanol, water and tetrahydrofuran, and the solution is heated to 60 degrees Celsius for 24 hours. The solution is cooled and then diluted with water followed by 10% aqueous hydrochloric acid to bring the pH value to 3. The resulting solution is extracted with ethyl acetate. The organic extracts are combined and washed with water and brine, and dried over sodium sulfate to afford the desired carboxylic acid.
- Part E To a solution of the carboxylic acid of Part D in N,N-dimethylformamide are added 4- methylmorpholine (6.0 equivalents), N- hydroxybenzotriazole (1.2 equivalents), and l-[3- (dimethylamino) propyl] -3 -ethylcarbodiimide hydrochloride (1.3 equivalents), followed by O- (tetrahydro-2H-pyran-2-yl) hydroxylamine (1.3 equivalents) . After stirring for 2 days at ambient temperature the solution is concentrated. Water is added and the mixture is extracted with ethyl acetate. The organic extracts are washed with water and brine, and dried over sodium sulfate. Concentration affords a residue that is chromatographed on silica gel eluting with ethyl acetate/hexane (20/80 to 90/10) as eluate to afford the THP-protected hydroxamate derivative.
- 4- methylmorpholine 6.0 equivalents
- Part F To a solution of the THP-protected hydroxamate of Part E in 1,4 -dioxane is added 4 N HCl in 1,4-dioxane (10 equivalents), and the solution is permitted to stir at ambient temperature for 3 hours. Concentration gives a residue that is then triturated with diethyl ether to afford the title compound.
- Part B To a solution of the bromide of part A (20 mmol, 7.2 g) in dioxane (20 mL) was added 4N HCl (50 mL) . The solution was stirred at ambient temperature for two hours, then concentrated to give a solid. The solid was triturated with diethyl ether, affording the desired piperidine hydrochloride (5.8 g 99%) .
- Part C To a solution of 3,4- dimethoxybenzenesulfonyl chloride (18 mmol, 4.26 g) in acetonitrile (75 mL) was added the hydrochloride from part B (20 mmol, 5.8 g) , followed by triethylamine (36 mmol, 7.5 mL) and N,N- dimethylaminopyridine (100 mg) . The solution was stirred at ambient temperature for 75 hours. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (300 mL) . The ethyl acetate layer was washed with brine (100 mL) , and dried over magnesium sulfate.
- Part D To a solution of the compound of Part C (2.96 g, 6.49 mmol) in ethylene glycol dimethyl ether (30 mL) at ambient temperature under an atmosphere of nitrogen was added tetrakis (triphenylphosphine) palladium (0) (0.375 g, 0.325 mmol) .
- Part E To a solution of the biphenyl of Part D (2.85 g, 5.89 mmol) in THF (80 mL) at -80 degrees Celsius under a nitrogen atmosphere was added a solution of 1.6 M n-butyllithium in hexane (5.17 mL, 8.27 mmol) . After stirring at ambient temperature for 30 minutes, the solution was cooled to -80 degrees Celsius and carbon dioxide was bubbled into the solution for 7 minutes. The solution was diluted with IN HCl (50 mL) and extracted with ethyl acetate (3x50 mL) .
- Part F To a solution of the carboxylic acid of Part E (2.92 g, 5.53 mmol) and DMF (2 drops, catalytic amount) in 1 , 2 -dichloroethane (50 mL) was added oxalyl chloride (4.07 mL, 46.7 mmol). After stirring for 1.5 hours at ambient temperature under a nitrogen atmosphere, the solution was concentrated in vacuo to a yellow oil.
- N- methylmorpholine (1.57 mL, 14.2 mmol)
- O- (tetrahydro- 2H-pyran-2-yl) hyroxylamine (1.66 g, 14.2 mmol)
- 1 , 2 -dichloroethane (19 mL)
- the mixture was diluted with water (150 mL) and extracted with ethyl acetate (3x50 mL) .
- Part G To a solution of acetyl chloride (2.61 mL, 38.1 mmol) in MeOH (39 mL) was added the 0- protected hydroxamate of Part F (2.39 g, 3.81 mmol) and stirred at ambient temperature under a nitrogen atmosphere for 1.5 hours. The solution was concentrated, triturated with ether, concentrated, and dried to give a white solid. Chromatography (on silica, MeOH/CHCl 3 ) provided the title compound as a white solid(1.36 g, 66% yield); Anal, calcd for C 27 H 30 N 2 O 8 S: C, 59.77; H, 5.57; N, 5.16; S, 5.91. Found: C, 57.60; H, 5.17; N, 5.04; S, 5.67. MS (EI) MH+ calcd. for C 27 H 30 N 2 O 8 S 543
- Part A A solution of 1- [ (3 -fluorophenyl ) - sulfonyl] -4- [4 (trifluoromethyl ) phenoxy] piperidine
- Part B To a solution of the ether of Part A (6.59 g, 14.3 mmol) in THF (120 mL) at -10 degrees Celsius under a nitrogen atmosphere was added a solution of 1.7 M t-butyllithium in pentane (16.8 L, 26.8 mmol) . After stirring at -60 degrees Celsius for 30 minutes, carbon dioxide was bubbled into the solution for 7 minutes, the resulting solution was poured into a solution of IN HCl (100 mL) and water (500 mL) , and extracted with ethyl acetate (3x100 mL) . The organic layer was washed with IN HCl (100 mL) , water (2x100 mL) and brine (100 mL) , dried with MgS0 4 , and concentrated in vacuo . Chromatography
- Part C To a solution of the carboxylic acid of Part B (5.45 g, 10.8 mmol) and DMF (4 drops, catalytic amount) in dichloromethane (99 mL) was added oxalyl chloride (8.03 mL, 92.0 mmol) . After stirring for 2 hours at ambient temperature, the solution was concentrated in vacuo to a dark brown mixture . To the mixture were added N- methylmorpholine (4.76 mL, 43.3 mmol), O- (tetrahydro- 2H-pyran-2-yl) hyroxylamine (5.07 g, 43.3 mmol), and dichloromethane (77 mL) .
- Part D A solution of acetyl chloride (5.90 mL, 86.3 mmol) in MeOH (89 mL) was added to the O- protected hydroxamate of Part C (5.20 g, 8.63 mmol) and stirred at ambient temperature for 3 hours. The solution was concentrated, triturated with ether, and concentrated to give an off white solid. Chromatography (on silica, MeOH/methylene chloride) provided the title compound as a white solid (2.25 g, 50% yield); Anal, calcd for C 22 H 25 N 2 0 7 S : C, 50.96; H, 4.86; N, 5.40; S, 6.18. Found: C, 50.57; H, 4.91; N, 5.37; S, 6.08. S (EI) MH+ calcd. for C 22 H 25 N 2 0 7 S 519, found 519.
- Part A 4-Hydroxypiperidine (55 mmol, 5.56 g) was diluted with acetonitrile (100 mL) , triethylamine (55 mmol, 7.7 mL) , and N,N-dimethyl- aminopyridine (500 mg) . 3 , 4-dimethoxy-benzenesulfonyl chloride (50 mmol, 11.84 g) was added. The mixture was stirred overnight (about 18 hours) , then concentrated by rotary evaporation. The residue was diluted with water (100 mL) and extracted with dichloromethane (2 X 150 mL) . The combined organic phases were dried using magnesium sulfate, filtered through a silica plug, and concentrated to afford the desired alcohol as a foam (7.31 g, 51%) .
- Part B The alcohol from Part A (6.39 g, 22.4 mmol) was combined with methylene chloride (65 mL) and triethylamine (3.46 mL, 25 mmol) . The solution was chilled to zero degrees Celsius. Methanesulfonyl chloride (1.79 mL, 23 mmol) was added. The reaction was stirred at ambient temperature for 4 hours, then diluted to 150 ml with additional methylene chloride, and washed with water (2 X 25 mL) . The organic phase was dried over magnesium sulfate, filtered through silica, and concentrated to provide the mesylate as a white solid (3.51 g, 41%) .
- Part C 60% Sodium hydride in mineral oil (324 mg, 8.1 mmol) was washed with hexanes . The washed hydride was covered with N,N-dimethylformamide (12 mL) and chilled to zero degrees Celsius.
- Part D The sulfide was dissolved in tetrahydrofuran (24 mL) and cooled to zero degrees Celsius. T-BuLi (1.7 M in pentane, 4.1 mL) was added over 1 minute. After 15 minutes, the reaction was quenched with carbon dioxide gas. After 10 minutes, the mixture was acidified using concentrated HCl, concentrated, and chromatographed to give the desired acid as a foam (1.067 g, 70%)
- Part E The acid from Part C was diluted with methylene chloride (15 mL) . Three drops of N,N- dimethylformamide were added, followed by oxalyl chloride (0.35, 4 mmol) . The reaction was stirred at ambient temperature for 2 hours, then concentrated. The crude acid chloride was added using about 3 mL of methylene chloride to a mixture of tetrahydropyran- hydroxylamine (0.47 g, 4 mmol), pyridine (0.47 ml, 6 mmol) and acetonitrile (3 mL) . The mixture was stirred overnight (about 18 hours), then subjected to aqueous extraction (50 mL methylene chloride/50 mL water) . The organic phase was dried over magnesium sulfate, concentrated, and chromatographed to afford the O-THP hydroxamate as a foam (619 mg) .
- Example 25 6- [ [4- [ (3 ' -Dimethoxy [1 , 1 ' -biphenyl] -4- yl) -1 -piperidinyl] sulfonyl] -N hydroxy-
- Example 30 2 , 3 -Dihydro-N-hydroxy-6- [ (4-methoxy- 1 -piperidinyl ) sul fonyl ] - 1 , 4 -benzodioxin- 5 - carboxamide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US310813 | 1989-02-13 | ||
US31081399A | 1999-05-12 | 1999-05-12 | |
PCT/US2000/006713 WO2000069819A1 (en) | 1999-05-12 | 2000-05-12 | Hydroxamic acid derivatives as matrix metalloprotease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1177173A1 true EP1177173A1 (en) | 2002-02-06 |
Family
ID=23204225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00931910A Withdrawn EP1177173A1 (en) | 1999-05-12 | 2000-05-12 | Hydroxamic acid derivatives as matrix metalloprotease inhibitors |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1177173A1 (en) |
JP (1) | JP2002544257A (en) |
KR (1) | KR20020009610A (en) |
CN (1) | CN1360577A (en) |
AR (1) | AR035624A1 (en) |
AU (1) | AU781339B2 (en) |
BR (1) | BR0011291A (en) |
CA (1) | CA2373500A1 (en) |
HK (1) | HK1045501A1 (en) |
MX (1) | MXPA01011481A (en) |
NZ (1) | NZ515197A (en) |
WO (1) | WO2000069819A1 (en) |
ZA (1) | ZA200109007B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
US7115632B1 (en) * | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US6696449B2 (en) * | 1997-03-04 | 2004-02-24 | Pharmacia Corporation | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
AU3312100A (en) * | 1999-03-22 | 2000-10-09 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
US6541661B1 (en) | 1999-11-23 | 2003-04-01 | Methylgene, Inc. | Inhibitors of histone deacetylase |
JP4975941B2 (en) * | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | (E) -N-hydroxy-3- (3-sulfamoyl-phenyl) acrylamide compound and therapeutic use thereof |
DK1335898T3 (en) | 2000-09-29 | 2006-04-03 | Topotarget Uk Ltd | Carbamic acid compounds comprising an amide bond as HDAC inhibitors |
US6683078B2 (en) * | 2001-07-19 | 2004-01-27 | Pharmacia Corporation | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
CA2465328C (en) * | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
ATE399012T1 (en) * | 2002-04-03 | 2008-07-15 | Topotarget Uk Ltd | CARBAMINIC ACID DERIVATIVES CONTAINING A PIPERAZINE LINKAGE AS HDAC INHIBITORS |
WO2003091247A2 (en) | 2002-04-25 | 2003-11-06 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
US7465719B2 (en) | 2003-01-17 | 2008-12-16 | Topotarget Uk Limited | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors |
KR100621480B1 (en) * | 2005-03-16 | 2006-09-19 | 최우혁 | Grain grader for sort out crushed rice |
EP1866298A2 (en) * | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
EP1908751A1 (en) * | 2006-10-03 | 2008-04-09 | EOS S.p.A. | N-hydroxy benzamides with antitumour activity |
US8796330B2 (en) | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
CN106699635B (en) * | 2015-11-12 | 2019-10-22 | 北京福元医药股份有限公司 | A method of preparing Delamanid intermediate |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000029984A (en) * | 1996-08-14 | 2000-05-25 | 사라 엔 람베쓰 | Substituted pyrimidine derivatives and their pharmaceutical use |
IL131494A (en) * | 1997-03-04 | 2005-06-19 | Monsanto Co | N-hydroxy 4-sulfonyl butanamide compounds and their use to prepare medicaments for treating conditions associated with matrix metalloproteinase activity |
CZ20012320A3 (en) * | 1998-12-23 | 2002-10-16 | G. D. Searle & Co. | Medicament containing cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy when treating neoplasia |
-
2000
- 2000-05-12 KR KR1020017014418A patent/KR20020009610A/en not_active Application Discontinuation
- 2000-05-12 CA CA002373500A patent/CA2373500A1/en not_active Abandoned
- 2000-05-12 MX MXPA01011481A patent/MXPA01011481A/en not_active Application Discontinuation
- 2000-05-12 NZ NZ515197A patent/NZ515197A/en unknown
- 2000-05-12 EP EP00931910A patent/EP1177173A1/en not_active Withdrawn
- 2000-05-12 AU AU49718/00A patent/AU781339B2/en not_active Ceased
- 2000-05-12 CN CN00809958A patent/CN1360577A/en active Pending
- 2000-05-12 JP JP2000618236A patent/JP2002544257A/en active Pending
- 2000-05-12 AR ARP000102311A patent/AR035624A1/en unknown
- 2000-05-12 WO PCT/US2000/006713 patent/WO2000069819A1/en not_active Application Discontinuation
- 2000-05-12 BR BR0011291-7A patent/BR0011291A/en not_active IP Right Cessation
-
2001
- 2001-10-31 ZA ZA200109007A patent/ZA200109007B/en unknown
-
2002
- 2002-08-06 HK HK02105758.9A patent/HK1045501A1/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0069819A1 * |
Also Published As
Publication number | Publication date |
---|---|
KR20020009610A (en) | 2002-02-01 |
ZA200109007B (en) | 2003-01-31 |
AR035624A1 (en) | 2004-06-23 |
MXPA01011481A (en) | 2005-06-20 |
AU4971800A (en) | 2000-12-05 |
BR0011291A (en) | 2002-05-14 |
AU781339B2 (en) | 2005-05-19 |
WO2000069819A1 (en) | 2000-11-23 |
JP2002544257A (en) | 2002-12-24 |
CA2373500A1 (en) | 2000-11-23 |
HK1045501A1 (en) | 2002-11-29 |
NZ515197A (en) | 2004-03-26 |
CN1360577A (en) | 2002-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6656954B2 (en) | Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds | |
US7115632B1 (en) | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | |
EP1177173A1 (en) | Hydroxamic acid derivatives as matrix metalloprotease inhibitors | |
EP1406626A2 (en) | Sulphonyl aryl hydroxamates and their use as mmp inhibitors | |
US6476027B1 (en) | N-hydroxy 4-sulfonyl butanamide compounds | |
US6638952B1 (en) | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds | |
US6362183B1 (en) | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds | |
US6683078B2 (en) | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | |
US6794511B2 (en) | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | |
AU737329C (en) | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011127 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20011127;LT PAYMENT 20011127;LV PAYMENT 20011127;MK PAYMENT 20011127;RO PAYMENT 20011127;SI PAYMENT 20011127 |
|
17Q | First examination report despatched |
Effective date: 20031128 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: G.D. SEARLE LLC. |
|
17Q | First examination report despatched |
Effective date: 20031128 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070320 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1045501 Country of ref document: HK |